1 Germline loss-of-function *PAM* variants are enriched in subjects with pituitary

2 hypersecretion

3

Giampaolo Trivellin^{1,2*}, Adrian F. Daly³, Laura C. Hernández-Ramírez^{4,5}, Elisa Araldi⁶, 4 Christina Tatsi⁵, Ryan K. Dale⁷, Gus Fridell⁷, Arjun Mittal⁷, Fabio R. Faucz^{5,8}, James R. 5 Iben⁸, Tianwei Li⁸, Eleonora Vitali², Stanko S. Stojilkovic⁹, Peter Kamenicky¹⁰, Chiara 6 Villa^{11,12}, Bertrand Baussart^{12,13}, Prashant Chittiboina¹⁴, Camilo Toro¹⁵, William A. Gahl¹⁵, 7 Erica A. Eugster¹⁶, Luciana A. Naves¹⁷, Marie-Lise Jaffrain-Rea^{18,19}, Wouter W. de Herder²⁰, 8 Sebastian JCMM Neggers²⁰, Patrick Petrossians³, Albert Beckers³, Andrea G. Lania^{1,2}, 9 Richard E. Mains²¹, Betty A. Eipper²², Constantine A. Stratakis^{5,23,24} 10 11 12 ¹Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 13 20072 Pieve Emanuele – Milan, Italy 14 ²IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano – Milan, Italy 15 ³Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, 16 Domaine Universitaire du Sart-Tilman, 4000 Liège, Belgium 17 ⁴Red de Apoyo a la Investigación, Coordinación de la Investigación Científica, Universidad 18 Nacional Autónoma de México e Instituto Nacional de Ciencias Médicas y Nutrición 19 Salvador Zubirán. Tlalpan, CDMX 14080, Mexico [°]Section on Endocrinology and Genetics, *Eunice Kennedy Shriver* National Institute of Child 20 21 Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD 22 20892, USA 23 ⁶Energy Metabolism Laboratory, Institute of Translational Medicine, Department of Health 24 Sciences and Technology, Swiss Federal Institute of Technology (ETH) Zurich, 25 Schwerzenbach, CH-8603, Switzerland 26 ¹Bioinformatics and Scientific Programming Core, *Eunice Kennedy Shriver* National Institute 27 of Child Health and Human Development (NICHD), National Institutes of Health (NIH), 28 Bethesda, MD 20892, USA

29	⁸ Molecular Genomics Core, Eunice Kennedy Shriver National Institute of Child Health and
30	Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, 20892,
31	USA
32	⁹ Section on Cellular Signaling, <i>Eunice Kennedy Shriver</i> National Institute of Child Health and
33	Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD 20892,
34	USA
35	¹⁰ Université Paris-Saclay, INSERM, Physiologie et Physiopathologie Endocriniennes, 94270
36	Le Kremlin-Bicêtre, France
37	¹¹ Département de Neuropathologie de la Pitié Salpêtrière, Hôpital de la Pitié-Salpêtrière -
38	APHP Sorbonne Université, 47-83 Bd de l'Hôpital 75651, Paris, France
39	¹² INSERM U1016, CNRS UMR 8104, Institut Cochin, 75014 Paris, France
40	¹³ Service de Neurochirurgie, Hôpital Pitié-Salpêtrière, AP-HP Sorbonne, 47-83 Boulevard de
41	l'Hôpital, 75651 Paris, France
42	¹⁴ Neurosurgery Unit for Pituitary and Inheritable Diseases and Surgical Neurology Branch,
43	National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health
44	(NIH), Bethesda, MD 20892, USA
45	¹⁵ NIH Undiagnosed Diseases Program, Office of the Clinical Director, National Human
46	Genome Research Institute (NHGRI), National Institutes of Health (NIH), Bethesda, MD
47	20892, USA
48	¹⁶ Division of Endocrinology & Diabetes, Department of Pediatrics, Riley Hospital for Children
49	at IU Health, Indiana University School of Medicine, Indianapolis, IN 46202, USA
50	¹⁷ Service of Endocrinology, University Hospital, Faculty of Medicine, University of Brasilia,
51	70910900 Brasilia, Brazil
52	¹⁸ Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila,
53	67100 L'Aquila, Italy
54	¹⁹ Neuromed Institute, Istituto di Ricovero e Cura a Carattere Scientifico, 86077 Pozzilli, Italy
55	²⁰ Department of Medicine, Section Endocrinology, Pituitary Center Rotterdam, Erasmus
56	University Medical Center, 3000 CA Rotterdam, the Netherlands

- ²¹Department of Neuroscience, UConn Health, 263 Farmington Avenue, Farmington, CT
- 58 06030, USA
- ²²Department of Molecular Biology and Biophysics, UConn Health, 263 Farmington Avenue,
- 60 Farmington, CT 06030, USA
- 61 ²³Human Genetics & Precision Medicine, IMBB, Foundation for Research & Technology
- 62 Hellas, 70013 Heraklion, Crete, Greece
- 63 ²⁴Research Institute, ELPEN, Pikermi, 19009 Athens, Greece
- 64

65 Author contributions

- 66 GT and CAS conceived the study. GT, LCHR, AFD, RKD, GF, AM, BAE, REM, EA, and
- 67 CAS formulated study hypotheses and conceived and designed the experiments. GT,
- 68 LCHR, GF, AM, JRI, TL, CT (Camilo Toro), EA, FRF, CT, BAE, and REM performed the
- 69 experiments. GT, LCHR, AFD, GF, EA, FRF, CT (Camilo Toro), CT (Christina Tatsi), BAE,
- and REM analyzed the data. GT, AFD, EA, BAE, and REM constructed the figures. GT
- 71 wrote the original manuscript draft. All authors reviewed and edited the manuscript.
- 72

73 *Corresponding author and person to whom reprints should be addressed:

- 74 Dr. Giampaolo Trivellin, PhD
- 75 Department of Biomedical Sciences
- 76 Humanitas University
- 77 Via Rita Levi Montalcini 4
- 78 20072 Pieve Emanuele Milan, Italy
- 79 E-mail: giampaolo.trivellin@hunimed.eu
- 80
- 81 Manuscript type: Original article
- 82 Short title: Pituitary hypersecretion is associated to PAM variants
- 83 Keywords: peptidylglycine α-amidating monooxygenase, amidation, gigantism, acromegaly,
- 84 Cushing disease, pituitary tumors

- 85 Abstract word count: 249
- 86 Main text word count: 10335
- 87 Figure number: 8
- 88 Table number: 3
- 89 References: 80

91 Abstract

92 Pituitary adenomas (PAs) are common, usually benign tumors of the anterior pituitary gland 93 which, for the most part, have no known genetic cause. PAs are associated with major 94 clinical effects due to hormonal dysregulation and tumoral impingement on vital brain 95 structures. Following the identification of a loss-of-function variant (p.Arg703Gln) in the PAM 96 gene in a family with pituitary gigantism, we investigated 299 individuals with sporadic PAs 97 and 17 familial isolated pituitary adenomas kindreds for PAM variants. PAM encodes a 98 multifunctional protein responsible for the essential C-terminal amidation of secreted 99 peptides.

100 Genetic screening was performed by germline and tumor sequencing and germline copy 101 number variation (CNV) analysis. No germline CNVs or somatic single nucleotide variants 102 (SNVs) were identified. We detected seven likely pathogenic heterozygous missense, 103 truncating, and regulatory SNVs. These SNVs were found in sporadic subjects with GH 104 excess (p.Gly552Arg and p.Phe759Ser), pediatric Cushing disease (c.-133T>C and 105 p.His778fs), or with different types of PAs (c.-361G>A, p.Ser539Trp, and p.Asp563Gly). The 106 SNVs were functionally tested in vitro for protein expression and trafficking by Western 107 blotting, for splicing by minigene assays, and for amidation activity in cell lysates and serum 108 samples. These analyses confirmed a deleterious effect on protein expression and/or 109 function. By interrogating 200,000 exomes from the UK Biobank, we confirmed a significant 110 association of the PAM gene and rare PAM SNVs to diagnoses linked to pituitary gland 111 hyperfunction.

112 Identification of *PAM* as a candidate gene associated with pituitary hypersecretion opens the
possibility of developing novel therapeutics based on altering PAM function.

114

115 Introduction

116 The anterior pituitary gland plays a critical role in the dynamic control of major hormonal 117 systems, including growth, fertility, and stress responses. Anterior pituitary adenomas (PAs), 118 also called pituitary neuroendocrine tumors (PitNETs) [1], can be comprised of any of the 119 secretory cell subtypes, such as lactotropes that secrete prolactin, somatotropes (growth 120 hormone (GH)), corticotropes (adrenocorticotropic hormone (ACTH)), gonadotropes (follicle 121 stimulating hormone (FSH) and luteinizing hormone (LH)), and thyrotropes (thyroid 122 stimulating hormone (TSH)) [2]. Although they are usually benign lesions, PAs can have a 123 major impact through hormonal dysregulation and direct mass effects or invasion of brain 124 structures (optic chiasm, cavernous sinus). Epidemiologically, PAs are one of the most 125 frequent intracranial tumor types, and lead to clinically apparent disease with a frequency of 126 approximately 1 per 1,000 in the general population [3, 4]. Approximately 95% of PAs occur 127 sporadically. Hereditary PAs are often distinguished by a more severe clinical presentation, 128 such as an earlier age at onset, aggressive growth, larger size, and greater resistance to 129 treatment, and they might coexist with other syndromic components. Therefore, identification 130 of germline genetic causes can have implications for earlier identification and treatment of 131 affected individuals via genetic and clinical screening [5].

132

133 Germline changes like single nucleotide variants (SNVs) and/or copy number variants 134 (CNVs) in several genes have been implicated in familial isolated pituitary adenomas - FIPA 135 (AIP and GPR101 genes) [6, 7], familial syndromic pituitary adenomas (MEN1, CDKN1B, 136 PRKAR1A, PRKACB, SDHx, MAX, NF1, DICER1, TSC2, among others) and sporadic PAs 137 (AIP, GPR101, CABLES1). Recurrent somatic SNVs are found most frequently in GNAS and 138 USP8, in sporadic GH and ACTH-secreting PAs, respectively, and rarely in other genes [8]. 139 Despite these advances in establishing gene-disease links, the etiology of the overwhelming 140 majority of inherited and sporadic pituitary adenomas remains unknown. Hence, 141 identification and characterization of novel pathological genetic and genomic variants in PA 142 cohorts is medically significant.

143

144 In a large, international cohort of individuals with PAs, we identified germline loss-of-function 145 (LOF) variants of *PAM* (peptidylglycine α -amidating monooxygenase, MIM: 170270) in 146 subjects with familial and sporadic GH and ACTH hypersecretion. PAM is a highly 147 conserved, multifunctional protein that is increasingly recognized as an important regulator 148 of peptide amidation and secretion, among many other functions, in health and disease [9]. 149 We functionally evaluated 36 SNVs, demonstrating a deleterious effect on PAM 150 function/expression in eight variants. We also report a statistically significant association of 151 rare PAM SNVs with diagnoses of hyperfunction or tumors of the anterior pituitary gland. 152 These results suggest that pathogenic PAM variants can predispose and/or contribute to the 153 development of pathological pituitary hypersecretion.

155 Results

- 156 Identification of a pathogenic SNV in the PAM gene in a family with pituitary gigantism
- 157 The discovery cohort consisted of a three-member, non-consanguineous FIPA family that
- 158 was enrolled in the UDP of the NIHCC. The kindred consisted of monozygotic twin brothers
- 159 (individuals II-2 and II-3) and the eldest child of individual II-2, all of whom were affected by
- 160 childhood-onset pituitary gigantism (Table 1 and Figure 1A).

ID	Diagnosis	Gender	Pathogenic PAM variant(s)	Ethnicity	Age at disease onset (years)	Age at P/ diagnosis (years)	A Tumor s size (mm)	Treatment	Other clinical diagnoses
II-2*	GH excess (gigantism)	М	c.2108G>A (p.Arg703Gln)	Caucasian	<10	35-40	4	PegV	hypogonadism, adrenal nodules, pleural masses, severe osteopenia, muscular atrophy, diverticulosis
II-3*	GH excess (gigantism)	М	c.2108G>A (p.Arg703GIn)	Caucasian	<10	35-40	5x6	TSS, SSA, PV	hypogonadism, pancreatic and colon adenocarcinoma
II-3*	GH excess (gigantism)	Μ	c.2108G>A (p.Arg703GIn)	Caucasian	1-5	1-5	n.a.	SSA, PegV	hypotonia
1IH26	pediatric CD	F	c.2332-2A>T (p.His778fs)	Caucasian	10-15	10-15	3	TSS	scleroderma
NH36	pediatric CD	F	c133T>C	African-American	10-15	10-15	10	TSS (x3)	no
Belgium128	GH excess (gigantism)	М	c.2276T>C (p.Phe759Ser)	Latino	15-20	20's	Macro	TSS, SRL	none
3elgium197	GH excess (acromegaly)	Μ	c.1654G>A (p.Gly552Arg), c.1688A>G (p.Asp563Gly)	Caucasian	40's	40's	40	TSS, SRL, RTx	none

F, female; M, male; n.a., not applicable; PA, pituitary adenoma; PegV, pegvisomant; RTx, radiotherapy; SRL, somatostatin receptor ligand; TSS,

transsphenoidal surgery. *Member of the index FIPA kindred.

165 The monozygotic twins were born at 31 weeks gestation; their birth weights and lengths 166 were 1.96 kg and 48.3 cm (II-2) and 2.3 kg and 53.3 cm (II-3), respectively. They had two 167 normally sized siblings. Their father was 190 cm in height. Their mother was very tall [187 168 cm; +4.1 SDS using Centers for Disease Control (CDC) charts] but had no known history of 169 pituitary disease or established medical diagnosis of overgrowth; she died of colorectal 170 cancer in her 70's. The precise onset of the twins' excessive growth is uncertain, but it 171 began during childhood, such that by in their 10's they both measured >200 cm in height 172 (>+6.2 SDS). They were formally diagnosed with pituitary gigantism as adults (35-40 years), 173 at which time their final height was 231 cm (+7.8 SDS). At diagnosis they had clinical signs 174 of acromegaly including coarse facial features, frontal bossing, and enlarged extremities. 175 Elevated random GH (26 and 23.1 ng/mL) and IGF-1 (603 and 1130 ng/mL) levels were 176 noted, but prolactin levels were below normal levels. Only minor abnormalities were noted 177 on 3 Tesla pituitary magnetic resonance imaging (MRI), with possible small pituitary 178 microadenomas, 4 mm and 5 mm in maximum diameter (Figure 1B). Individual II-3 179 underwent transsphenoidal surgery, but no somatotropinoma tissue was identified by 180 histopathology. Both brothers required medical therapy with the GH-receptor antagonist, 181 pegvisomant, to reduce excess IGF-1. Colorectal and pancreatic adenocarcinomas were 182 diagnosed in patient II-3, and he subsequently died of the latter tumor in his 40's.

183 The third affected member was III-3, a male (son of II-2) who was born with normal length 184 and weight but developed marked overgrowth by the age of 12 months (Figure 1C). His 185 siblings are dizygotic twins with normal height. III-3 was diagnosed with GH and IGF-1 186 excess (random GH 30 ng/mL and IGF-1 389 ng/mL) before five years of age. An MRI 187 demonstrated a normal pituitary gland (Figure 1D). To control the excessive growth, the 188 patient was started on the long-acting somatostatin receptor ligand lanreotide autogel at a 189 dose of 90-120 mg/month sc. Despite this adult level dosing, the GH remained uncontrolled 190 and the IGF-1 rose to 487 ng/mL. During the lanreotide autogel treatment period, the growth 191 velocity remained accelerated, at 15.9-20 cm/year. Similar to II-2 and II-3, his condition 192 markedly improved on switching to pegvisomant (10-15 mg/day sc): IGF-1 rapidly fell from

193 500 ng/mL to 232 ng/mL and growth velocity decreased to 3.6-5.6 cm/year during
194 approximately five years of follow-up. His growth curves for height and weight remain above
195 the 99th centile but are no longer diverging (Figure 1E).

196

197 We conducted WES in peripheral blood-derived DNA isolated from the index cases (see the 198 Methods section for details). We applied a variant prioritization strategy (Figure S1 and 199 Table S3) and selected for further analysis a heterozygous missense SNV in PAM 200 (c.2108G>A, p.Arg703Gln), which was shared by both twins from generation II (Figure 1A). 201 DNA of their deceased mother was unavailable, so we could not confirm whether they 202 inherited the PAM variant from her or if it arose de novo; the father was WT. The 203 p.Arg703Gln variant was present in the other individual with gigantism, III-3, but also in III-1, 204 his younger brother (Figure 1A). Endocrine and growth studies showed that III-1 had no 205 evidence of growth excess or hormonal dysregulation at the time of study (age < 10 years). 206 All other family members studied were WT for PAM and had normal growth. Overall, these 207 results suggest incomplete penetrance. No other potentially pathogenic alterations in genes 208 were shared among the three affected members.



210

211 Figure 1. Clinical findings in the index family with pituitary gigantism

212 (A) Pedigree. Generation numbers are represented by Roman numerals, and individual numbers are 213 in Arabic numerals. The proband is II-2, indicated by the black arrow. Open square/circle, unaffected 214 male/female; filled square, affected male. PAM mutational status is shown under each screened 215 individual. In (B) the white arrowhead points to a possible 4 mm lesion, seen in II-2. (C) Growth chart 216 for individual III-3 before and after medical interventions. (D) A sagittal T2-weighted MRI of individual 217 III-3 that was performed before medical therapy began did not reveal a pituitary lesion. (E) Time 218 course of the effects of treatment modalities on GH (left axis) and IGF-1 (right axis) in individual III-3. 219 The rapid decrease of IGF-1 after switching from lanreotide (LAN) to pegvisomant (PegV) is evident.

221 The PAM variant was notable among the 27 candidates due to its strong expression in 222 neuroendocrine tissues and gene function. As reported in The Human Protein Atlas, the 223 pituitary is among the tissues displaying the strongest PAM mRNA and protein expression 224 signal in human and other mammals. PAM is highly expressed in all pituitary cell types, 225 including folliculostellate cells (Figure S2A), where it plays a crucial function in post-226 translational hormone processing and secretion [10, 11]. Staining for PAM and GM130, a 227 cis-Golgi marker, in normal adult human pituitary cells showed diffuse cytoplasmic 228 expression for PAM that partially overlapped the Golgi (Figure S2B), reflecting the 229 established trafficking of PAM within the secretory pathway observed in rat pituitary cells.

PAM is a multifunctional protein that contains two enzymatic domains, peptidylglycine αhydroxylating monooxygenase (PHM) and peptidyl-α-hydroxyglycine α-amidating lyase
(PAL); acting sequentially, the two domains generate C-terminally amidated peptides [10].
The p.Arg703Gln variant – located in the PAL domain (Figure 2A) – has an extremely low
minor allele frequency in controls (MAF: 0.0013%), no homozygous variant entries in
gnomAD, and is bioinformatically predicted to be pathogenic (Table 2).

DNA change	Protein change	SNP ID	Location in gene	Location in protein	MAF in our cohort (%)	Global Control MAF (%)	Highest Control Population MAF (%)	# of homozygotes in gnomAD	P- value	In silico prediction	Individuals harboring the variant	This artic
c607A>G [†]	n.a.	rs76396377	promoter	n.a.	0.4	1.479	2.943 (African)	24	n.s.	1 TF replaced	1 from 1 FIPA (PRL)	le is
c550G>T [‡]	n.a.	rs1007572715	promoter	n.a.	0.4	0.0072	0.0415 (South Asian)	0	<0.05	2 TFs lost	1 acro	a U
c361G>A	n.a.	rs143617515	5'UTR (exon 1)	n.a.	1.21	0.6275	3.647 (Finnish)	12	n.s.	2 TFs lost, 4 TFs created	2 gigantism, 1 NFPA	S G
c133T>C *	n.a.	rs1413721196	5'UTR (exon 1)	n.a.	0.25	0.0007	0.0015 (European)	0	<0.05	1 TF lost	1 pediatric CD	over
c109G>C	n.a.	Novel	5'UTR (exon 1)	n.a.	0.25	n.a.	n.a.	n.a.	n.a.	1 TF replaced	1 acro	.nme
c35C>G	n.a.	rs201016377	5'UTR (exon 1)	n.a.	0.15	0.0749	0.9040 (Finnish)	1 (Finnish)	n.s.	n.a.	1 gigantism	ent w
c.79G>A **	p.Val27lle	rs199856250	exon 1	proregion	0.16	0.0004	0.0008 (European)	0	<0.05	VUS (1, 6, 12)	1 acro	vork
c.92T>A	p.Phe31Tyr	rs114014768	exon 2	linker region	0.63	0.8654	2.814 (African)	19	n.s.	likely benign (0, 1, 16)	2 acro, 1 gigantism, 1 pediatric CD	t is
c.145G>C	p.Val49Leu	rs2230458	exon 2	PHMcc	0.94	0.9278	1.803 (Finnish)	5 (European)	n.s.	likely benign (0, 2, 17)	2 gigantism, 3 pediatric CD, 1 PR	5 not
c.239G>A	p.Arg80Gln	rs753307443	exon 3	PHMcc	0.16	0.0026	0.0066 (Latino)	0	<0.05	likely benign (1, 5, 13)	1 from 1 FIPA (GH excess)	sub
c.718C>T ^{††}	p.His240Tyr	rs761898981	exon 9	PHMcc	0.15	0.0039	0.0478 (Other)	0	<0.05	VUS (0, 11, 7)	1 gigantism	ject
c.731T>C **	p.Val244Ala	rs201009674	exon 10	PHMcc	0.16	0.0533	0.6632 (Ashkenazi Jewish)	0	n.s.	likely pathogenic (6, 12, 0)	1 pediatric CD	
c.1235C>T **	p.Pro412Leu	rs761619241	exon 14	linker region	0.16	0.0016	0.0029 (Latino)	0	<0.05	likely pathogenic (6, 9, 4)	2 from 1 FIPA (heterogeneous)	Syrig
c.1354A>G	p.lle452Val	rs145710876	exon 14	linker region	0.16	0.0151	0.0555 (African)	0	n.s.	likely benign (0, 0, 18)	1 gigantism	ht ur
c.1473A>C	p.Glu491Asp	rs61736661	exon 14	linker region	0.16	0.6662	1.241 (European)	8 (European)	n.s.	likely benign (0, 1, 16)	1 from 1 FIPA (PRL)	ົງder
c.1616C>G	p.Ser539Trp	rs78408340	exon 16	PALcc	0.15	0.4169	0.7250 (European)	2 (European)	n.s.	likely pathogenic (10, 6, 2)	1 acro	171
c.1654G>A ^{‡‡}	p.Gly552Arg	rs201249509	exon 16	PALcc	0.15	0.0053	0.0103 (European)	0	<0.05	likely pathogenic (10, 6, 2)	1 acro	JSC .
c.1688A>G	p.Asp563Gly	rs35658696	exon 16	PALcc	4.00	3.109	5.657 (European)	108	n.s.	likely pathogenic (4, 11, 1)	13 acro, 5 gigantism, 4 PRL, 4 CD (3 pediatric, 1 silent)	105 ar
c.1921G>C	p.Gly641Arg	rs775364358	exon 18	PALcc	0.15	0.0033	0.0197 (Latino)	0	<0.05	likely benign (0, 3, 16)	1 PRL	nd is
c.2108G>A	p.Arg703Gln	rs761130902	exon 19	PALcc	0.15	0.0013	0.0193 (East Asian)	0	<0.05	likely pathogenic (10, 9, 0)	4 (3 affected) from 1 FIPA (gigantism)	also r
c.2276T>C ^{††}	p.Phe759Ser	rs375364507	exon 20	PALcc	0.15	0.0092	0.0206 (European)	0	n.s.	likely pathogenic (7, 11, 0)	1 gigantism	nad
c.2332-2A>T §	p.His778fs	rs1006675725	intron 20	PALcc	0.15	0.0007	0.0015 (European)	0	<0.05	pathogenic (disrupts canonical SA)	2 (1 pediatric CD and unaffected parent)	e availa
c.*1455C>T	n.a.	rs146343559	3'UTR (exon 25)	n.a.	0.67	0.0362	0.1047 (Latino)	0	n.s.	creates new miRNA binding sites	1 pediatric CD	able

000 Table Dui a -I I-. : . 41. DA 14. - -- ! -£.... 41.0 -11-

Variants were annotated using the NC_000005.9(NM_000919.3) reference sequence. All variants were observed in heterozygosis. MAFs were retrieved from

- the gnomAD database ver. 3.1.2. "European" excludes the Finnish population; "African" includes African-American; "Latino" includes Admixed American. For
- *in silico* predictions, the computational verdict was based on the combined outputs of 19 softwares available in Varsome (within parentheses, the first number
- represents the pathogenic verdicts, the second number the uncertain verdicts, and the third number the benign verdicts) for all missense variants; for the truncating and 3'UTR variants we used Alamut predictions; for the regulatory variants we used Genomatix MatInspector, Individual variant allele frequencies
- truncating and 3'UTR variants we used Alamut predictions; for the regulatory variants we used Genomatix MatInspector. Individual variant allele frequenciation in the study population were compared with the global frequencies reported in gnomAD using the Fisher's exact test or the chi-square test, as appropriate.
- acro, acromegaly; CD, Cushing disease; FIPA, familial isolated pituitary adenoma; MAF, minor allele frequency; n.a., not available/applicable; NFPA, non-
- 244 functioning pituitary adenoma; n.s., not significant; PALcc, catalytic core of peptidyl- α -hydroxyglycine α -amidating lyase; PHMcc, catalytic core of
- 245 peptidylglycine α-hydroxylating monooxygenase; PRL, prolactinoma; SA, splice acceptor site; TF, transcription factor; VUS, variant of uncertain significance.
- ¹This individual harbors the *PAM* p.Glu491Asp variant in exon 14.
- [‡]This individual harbors the *PAM* p.Val49Leu variant in exon 2.
- ^{*}This individual harbors the *PAM* p.Phe31Tyr variant in exon 2 and a somatic heterozygous p.Ser718del variant in the *USP8* gene [12].
- 249 ^{††}This individual is compound heterozygote for p.[His240Tyr];p.[Phe759Ser].
- 250 ^{‡‡}This individual is compound heterozygote for p.[Gly552Arg];p.[AspD563Gly].
- 251 ****This individual harbors a somatic heterozygous p.Ser718Pro variant in the USP8 gene [12].
- 252 ^{***}This individual harbors a somatic heterozygous p.Ser718del variant in the USP8 gene [12].
- 253 [§]Somatic hotspot variants in the USP8, BRAF, and USP48 genes were ruled out in this case.
- 254 **Allele frequency obtained from gnomAD ver. 2.1.1.

Arg703 is conserved throughout evolution (Figure 2B). Along with Tyr651, crystallographic studies identified Arg703 as part of the PALcc catalytic dyad; the catalytic activity of soluble recombinant rat PALcc, in which Arg703 was replaced by Ala or Gln, was greatly reduced [13], a result consistent with its location at the active site (Figure 2C). Altogether, these data suggested that a LOF *PAM* variant could be associated with pituitary gigantism, prompting us to pursue this lead.





PAL: Ser539Trp (Ex15/16); inactive



PAL:	PAL: Gly552Arg (Ex16); 6% active							
	549			552			555	
hum	I	G	L	G	Р	I	Е	
chi	I	G	L	G	Ρ	I	Е	
rat	R	G	L	G	Р	Т	Е	
apl	F	Q	D	S	Ρ	I	Т	
dro	I	Е	Υ	G	Ρ	I	Κ	
chl	Т	R	К	Е	Р	V	Р	

PAL: Asp563Gly (Ex16); 14% active							
	560			563			566
hum	L	V	1	D	Ρ	Ν	Ν
chi	L	V	I	D	Ρ	Ν	Ν
rat	L	V	I	D	Ρ	Ν	Ν
apl	L	V	Т	D	S	Т	G
dro	Υ	V	L	D	А	Κ	Т
chl	L	Ν	М	Ν	Р	D	Т

PAL: Arg703Gln (Ex19); inactive



PAL: Phe759Ser (Ex20):12% active

	756			759			762
hum	V	Q	G	F	V	М	Ν
chi	V	Q	G	F	V	М	Ν
rat	V	Q	G	F	V	М	Ν
apl	V	Q	G	F	Т	V	D
dro	V	R	G	F	Т	I	D
chl	Р	Т	Q	F	W	Т	L

С



262

264 Figure 2. Location and evolutionary conservation of the missense and frameshift *PAM* SNVs

265 that were functionally tested

266 (A) Schematic representation of the PAM gene (GenBank: NM 000919.3, PAM-1, 25 exons) and 267 encoded protein (NP_000910.2, 974 amino acids), including functional domains, with 15 missense 268 and a frameshift SNVs. Gene and protein structures were drawn with the Gene Structure Display 269 Server (GSDS ver. 2.0) [14]. Variants found to have deleterious effects on PAM function/expression 270 (p < 0.01) are shown in yellow lettering, while those without major effects are shown in white 271 lettering. Brackets identify the non-catalytic regions that precede PHMcc (N-Terminus) and follow 272 PALcc (C-Terminus); CD, cytosolic domain; CDS, coding sequence; PALcc, catalytic core of peptidyl-273 α-hydroxyglycine α-amidating lyase; PHMcc, catalytic core of peptidylglycine α-hydroxylating 274 monooxygenase; TMD, transmembrane domain; UTR, untranslated region. (B) Protein sequence 275 alignments for five of the variants with deleterious effects. Conserved affected residues are shown in 276 yellow. PAL activities, indicated in red, refer to functional experiments in PEAKrapid cells. (C) The 277 crystal structure of rat PALcc (PDB entry 3FW0) was used to contextualize the missense variants 278 categorized as likely pathogenic based on *in silico* analyses; the WT residue is shown on the left and 279 the mutant residue on the right. PAL folds as a β -propeller, with six blades (numbered 1 to 6) 280 positioned around a central cavity. The calcium and mercury ions are depicted as yellow and orange 281 spheres, respectively. The mercury ion was used instead of zinc to capture the binding of a 282 nonpeptide substrate, α-hydroxyhippuric acid, depicted in blue. The affected residues are highlighted 283 in purple (Ser or Trp 539), cyan (Gly or Arg 552), red (Asp or Gly 563), green (Arg or Gln 703), and 284 orange (Phe or Ser 759), along the ribbon visualization of WT rat PALcc in grey. Arg703 is positioned 285 at the active site and participates in substrate binding. Interestingly, p.Gly552Arg and p.Asp563Gly 286 are located on the same face of the β -propeller. C, C-terminus; N, N-terminus.

287

288 <u>PAM screening in a validation cohort revealed multiple likely pathogenic SNVs by *in silico* 289 <u>prediction</u> </u>

We next determined whether predicted pathogenic *PAM* variants are associated with other types of PAs, both hereditary and sporadic. To do so, we screened a diverse group of 326 germline and 60 tumor DNAs from PA patients for *PAM* SNVs (see the Methods section and Table S1 for details). Sequencing covered the *PAM* CDS and exon–intron junctions.

294 Germline CNVs at the PAM locus were analyzed by ddPCR in a cohort of 137 individuals 295 with PAs (16 with gigantism and 121 with different types of PAs). Germline DNA sequencing 296 detected 51 SNVs (Table 2 and Table S4). There were no germline CNVs, or 297 rare/pathogenic somatic DNA SNVs (data not shown). A subset of the germline SNVs (15 of 298 51) was prioritized for further screening together with the p.Arg703Gln variant (Table 2). This 299 selection was based on the following non-mutually exclusive criteria: MAF < 1%, in silico 300 analysis with multiple algorithms predicting a deleterious effect on PAM function or splicing, 301 and published functional data indicating pathogenicity [15]. To complement these data, we 302 used Clustal and structure-based analyses to identify variants that could impact protein 303 structure/function (Figure 2B and 2C, Figure S3). The remaining, non-characterized germline 304 SNVs are listed in Table S4.

305

306 Four of the 16 heterozygous nonsynonymous and splice site-affecting SNVs prioritized for 307 functional studies were in PHMcc and seven were in PALcc; the remainder were in the non-308 catalytic regions of PAM (Figure 2A). Based on in silico predictions, one of the four SNVs in 309 PHMcc and six of the seven in PALcc were predicted to be pathogenic (Table 2). The 310 prioritized variants were not significantly spatially clustered when we considered the 311 geometric mean distance between all pairs of variants normalized to cDNA length (p = 0.35). 312 However, when we classified the variants based on their location within the N-terminus, 313 PHMcc, linker, PALcc or C-terminus (Figure 2A), the N-terminus harbored more variants 314 than expected by random chance (p = 0.02, Table S5).

315

316 Expression of prioritized PAM SNVs revealed deficits in protein expression, enzymatic
 317 activity, and glycosylation

To understand the impact of the prioritized *PAM* variants on the function of this membrane enzyme, we transiently expressed each PAM-1 variant in PEAKrapid (HEK-293 derivative) cells. To facilitate accurate assessment of the PHM and PAL activity of each *PAM* variant, a non-ionic detergent (TX-100) was used to solubilize membrane proteins from a crude

322 particulate fraction (Figure 3A). PAM expression levels and protein integrity were evaluated 323 by Western blot analysis (Figure 3B) and PAM trafficking was assessed by analysis of N-324 and O-linked oligosaccharide maturation (Figure 3C and 3D). 325 To establish the efficacy of our expression system, we compared the properties of WT PAM 326 to those of missense PAM variants designed to inactivate PHMcc (p.Thr189lle) or PALcc 327 (p.His529Arg and p.Gly796Glu, Figure S4). PHM and PAL activity measurements for WT 328 PAM and for each engineered control were normalized to the expression of that PAM protein 329 [(PHM or PAL activity)/PAM protein], providing a measure of its specific activity; the PHM 330 and PAL specific activities of each engineered control were then compared to the PHM and 331 PAL specific activities of WT PAM. As expected, the PHM activity of the p.Thr189lle mutant 332 and the PAL activity of the p.His529Arg and p.Gly796Glu mutants were reduced more than 333 ten-fold compared to WT PAM (Figure S4 and Table 3).

334

336	Table 3. Summary of effects on enzymatic activity and glycosylation for all PAM variants that
337	were functionally tested

PAM variant	PHM activity (% WT)	PAL activity (% WT)	PNGaseF (N-sugars)	Neuraminidase (sialic acid)
WT	100 <u>+</u> 2	100 <u>+</u> 3	yes	yes
Val27IIe	79 <u>+</u> 6	103 <u>+</u> 15	(yes)	(yes)
Phe31Tyr	76 <u>+</u> 16	84 <u>+</u> 1	(yes)	(yes)
Val49Leu	80 <u>+</u> 26	93 <u>+</u> 1	(yes)	(yes)
Arg80GIn	75 <u>+</u> 6	87 <u>+</u> 9	(yes)	(yes)
Thr189Ile [†]	6 <u>+</u> 3**	23 <u>+</u> 5**	yes	no
His240Tyr	111 <u>+</u> 24	98 <u>+</u> 22	yes	no
Val244Ala	113 <u>+</u> 32	80 <u>+</u> 10	(yes)	(yes)
Pro412Leu	81 <u>+</u> 32	85 <u>+</u> 28	(yes)	(yes)
lle452Val	112 <u>+</u> 45	113 <u>+</u> 30	(yes)	(yes)
Glu491Asp	133 <u>+</u> 75	138 <u>+</u> 55	(yes)	(yes)
His529Arg [†]	41 <u>+</u> 13	7 <u>+</u> 1**	n.a.	n.a.
Ser539Trp	49 <u>+</u> 7**	0 <u>+</u> 1**	yes	no
Gly552Arg	41 <u>+</u> 6**	6 <u>+</u> 2**	yes	no
Asp563Gly	44 <u>+</u> 8**	14 <u>+</u> 3**	yes	no
Gly641Arg	104 <u>+</u> 0	116 <u>+</u> 10	(yes)	(yes)
Arg703GIn	92 <u>+</u> 17	0 <u>+</u> 1**	yes	yes
Phe759Ser	110 <u>+</u> 25	12 <u>+</u> 3**	yes	no
His778fs	23 <u>+</u> 3**	0 <u>+</u> 1**	n.a.	n.a.
Gly796Glu [†]	55 <u>+</u> 8	4 <u>+</u> 1**	(yes)	(yes)

Values are presented as mean <u>+</u> SEM. n.a., not assessed; WT, wild-type; (yes), based on SDS-PAGE profile.

[†]Engineered inactive mutants.

** p < 0.0001.

The structure of bifunctional PAM has not yet been experimentally determined, but for all three engineered variants, inactivating mutations placed into one domain resulted in a modest decrease in the activity of the other domain.

347 Activity and Western blot data for all studied SNVs are shown in Figure 3A and 3B, 348 respectively. No significant decrease in PHM activity was seen for SNVs p.Val27lle, 349 p.Phe31Tyr, p.Val49Leu, p.Arg80Gln, p.His240Tyr or p.Val244Ala. The three non-catalytic 350 linker domain SNVs tested exhibited no significant change in PHM or PAL activity and were 351 not extensively assayed. Six of the seven SNVs located in PALcc exhibited a dramatic 352 decrease in PAL activity. While some PALcc variants reduced PHM activity, others did not. 353 Although the PAL activity of p.Arg703Gln was undetectable and the PAL activity of 354 p.Phe759Ser was 12% of WT, their PHM activities were equal to that of WT. In contrast, the 355 dramatic reductions in PAL activity observed for p.Ser539Trp, p.Gly552Arg, p.Asp563Gly, 356 and p.His778fs were accompanied by at least a two-fold decrease in PHM activity. Normal 357 levels of both PHM and PAL activity were detected for p.Gly641Arg.

358

359 Maturation of N-linked oligosaccharides is generally completed only when the newly 360 synthesized protein exits the Golgi complex. Sialylation of both the N- and O-linked 361 oligosaccharides attached to rat PAM-1 occurs just before it exits the Golgi complex. The 362 stepwise manner in which the maturation of N- and O-linked glycans occurs often results in 363 glycoprotein heterogeneity, contributing to the diffuse bands observed for WT PAM and 364 many of the prioritized SNVs (Figure 3B, FLAG Ab and PHM Ab). In contrast, we 365 consistently observed a slightly smaller, more compact band for p.Thr189lle (engineered 366 variant), p.His240Tyr, p.Ser539Trp, p.Gly552Arg, p.Asp563Gly, and p.Phe759Ser.

367

368 Since altered access to the enzymes responsible for the maturation of N- and O-linked 369 glycans can reflect altered protein trafficking, we utilized PNGase F to remove N-linked 370 oligosaccharides and neuraminidase to remove sialic acid (Figure 3D). The 2 to 3 kDa 371 reduction in apparent molecular mass caused by PNGase F treatment demonstrated that the

engineered control lacking PHM activity (Thr189lle) and that each of these six variants had been N-glycosylated. As expected, neuraminidase treatment brought about a slight decrease in the apparent molecular mass of WT PAM. Strikingly, neuraminidase treatment failed to reduce the mass of any of these six SNVs, indicating that their glycans had not undergone normal sialylation. Despite this, p.His240Tyr, one of the variants exhibiting altered sialylation, had normal levels of both PHM and PAL activity. Altered trafficking in the secretory and/or endocytic pathway could limit sialylation.

379

380 A summary of the effect of each prioritized and engineered SNV on PAM expression,

381 enzymatic activity and oligosaccharide maturation is presented in Table 3.





386 from transiently transfected PEAKrapid cells were assayed for PHM activity and for PAL activity. Data

387 for the level of expression of WT PAM and each full-length variant were determined by quantifying the 388 FLAG-tag signal. Levels of p.His778fs were assessed as described in Methods. NT, not transfected; 389 WT, wild-type; **p < 0.0001. (B) PAM protein expression. SNV expression was assessed using a 390 FLAG tag antibody and an antibody to a peptide contained in PHMcc (JH246). The lines separating 391 WT and p.His240Tyr from p.Arg703Gln and p.Phe759Ser indicate that data for two intervening 392 samples were removed. Molecular weight standards are indicated. (C) PAM protein diagram, 393 indicating the location of the JH246 epitope (red horizontal line), the FLAG tag (grey diamond), and 394 the expected location of N- and O-glycans (blue and yellow freeform shapes, respectively). (D) 395 Glycosylation is altered in a subset of PAM variants. Cell lysates were treated with PNGase F or 396 neuraminidase as described in Methods. Proteins were visualized using the FLAG antibody. The 397 samples treated with Neuraminidase were analyzed on two separate gels, with the p.Arg703Gln 398 samples appearing in part on both gels. Con, control; In, Input; N-Gly, PNGase; Neur, neuraminidase; 399 NT, not transfected.

400

401 Three SNVs with diminished PAL activity were found in subjects with GH excess leading to 402 sporadic acromegaly (p.Ser539Trp, p.Gly552Arg) or gigantism (p.Phe759Ser). The relatively 403 common p.Asp563Gly variant (3.11% global MAF) was observed in persons with different 404 types of PAs (Table 2). Interestingly, two males with GH excess – one with acromegaly, and 405 one with gigantism - were compound heterozygotes for p.[Gly552Arg];[Asp563Gly] and 406 p.[His240Tyr];[Phe759Ser], respectively (Figure S5, Table 1). Although neither the PHM nor 407 PAL activity of p.His240Tyr (located in PHMcc) differed from WT, its heterogeneous band 408 pattern and lack of sensitivity to neuraminidase suggest structural alterations sufficient to 409 alter its trafficking (Figures 3A, 3B, and 3D); its significantly higher prevalence in the cohort 410 of subjects with PAs vs. controls, and the absence of homozygous individuals in gnomAD, 411 argue for its classification as a variant of uncertain significance (VUS). Further studies are 412 necessary to establish or disprove pathogenicity.

413

Three of the 15 SNVs were identified in individuals from FIPA families (one variant in each family, Table 2). SNVs p.Arg80Gln and p.Pro412Leu, which are very rare (MAF: 0.002%),

416 are significantly more prevalent in our cohort vs. controls, and are without homozygous 417 variant entries in gnomAD. The p.Arg80GIn SNV is located within PHMcc, while the 418 p.Pro412Leu and p.Glu491Asp SNVs are within the linker region. The p.Arg80Gln did not 419 segregate with the phenotype in the FIPA kindred and functional studies showed no 420 significant effect of p.Arg80Gln on PHM enzymatic activity. In contrast, the p.Pro412Leu 421 variant segregated with the FIPA phenotype and was seen in both the proband (acromegaly) 422 and the daughter (prolactinoma). Neither of the p.Pro412Leu or p.Glu491Asp variants in the 423 non-enzymatic linker region had a functional effect on PHM or PAL activity (Figure 3A, Table 424 3). Altogether, combining allele frequencies in our cohort vs. controls, in silico predictions, 425 functional data, and segregation analysis, our results indicate that the p.Arg80Gln and 426 p.Glu491Asp variants should be classified as likely benign, while p.Pro412Leu linker region 427 change is a VUS.

428

429 <u>Functional evaluation of a truncating variant associated with Cushing disease</u>

430 A variant affecting a canonical splice acceptor site (c.2332-2A>T) was present in a pediatric 431 female (NIH26) with ACTH excess leading to Cushing disease (Table 1). Her parent also 432 carried the variant and had evidence of disrupted circadian cortisol rhythm, based on 433 elevated midnight serum cortisol, but did not present clinically overt Cushing disease. The 434 variant was predicted to cause skipping of exon 21, generating a frameshift that introduces a 435 premature stop codon, eliminating the C-terminal region of PALcc (p.His778fs, Table 2 and 436 Figure S6). Skipping of exon 21 was confirmed by testing both the affected subject and 437 parent blood-extracted RNA (Figure 4A and 4B) and by using a minigene splicing assay 438 (Figure 4C). Transient expression of p.His778fs in PEAKrapid cells demonstrated, as 439 expected, that the truncated protein lacked detectable PAL activity; in addition, significantly 440 reduced levels of PHM activity were also observed (Figure 3A, Table 3). Western blotting 441 indicated that the mutant protein is produced but at lower levels than those observed for WT. 442 Moreover, the observed band was smaller than predicted (75 vs. 90 kDa, respectively),

443 suggesting that the mutant might lack some post-translational modifications and/or is



445



446

447 Figure 4. Functional studies of the c.2332-2A>T (p.His778fs) truncating variant

448 (A) RT-PCR analysis of PAM exon 21 splicing was performed using blood-extracted RNA from two 449 family members carrying the c.2332-2A>T variant (NIH26 and parent) and four WT control cDNAs. 450 Primers were designed on exons 17 and 22. Both carriers and controls showed a normally spliced 451 transcript (713 bp, upper band), while only the carriers showed an additional alternatively spliced 452 transcript lacking exon 21 (the 613 bp band, identified by the arrow). MW, molecular weight marker. 453 (B) The identity of the PCR products (panel A) was confirmed by Sanger sequencing. The arrows 454 point to the variant-specific peaks present only in the carriers. MUT, mutated; WT, wild-type. (C) 455 Minigene assay. After transfection into HEK-293 AD cells, mRNA synthesis from the plasmids using 456 the cells' own transcription and splicing machinery led to mRNA products containing (WT) or lacking 457 (variant) exon 21 of PAM flanked by two exons from the pSPL3 vector. The RT-PCR analysis of the 458 minigene transcripts was conducted using vector-specific primers. MW, molecular weight marker; 459 MOCK, cDNA from empty vector-transfected cells consisting of a 260 bp band made up of fragments 460 of pSPL3 exons; --, negative control (RT-PCR without cDNA). The lines separating MOCK and 461 negative control from WT and c.2332-2A>T indicate that data for intervening samples were removed. 462 (D) An expression vector lacking exon 21 of human PAM-1 (H778fs) was transiently expressed in 463 PEAKrapid cells. Proteins were visualized using an antibody to PHMcc (JH246 PHM Ab). Expression 464 of WT PAM produces a major band at 114 ± 1 kDa and a minor one at 105 kDa. The only band visible 465 in the cells expressing p.His778fs migrated at 75 kDa; after signal peptide removal, the mass

466 predicted for this protein – which includes only the first 777 residues of WT PAM-1 but extends 45

467 residues beyond residue 777 before reaching a stop codon – is 90.31 kDa. NT, not transfected.

468

469 Screening for PAM SNVs located in regulatory regions identified two variants that reduce

470 transcription

471 Next, we extended our screening to regulatory regions of PAM, namely the promoter and 472 untranslated regions (UTRs), to investigate whether there are SNVs with the potential to 473 impact PAM expression. We identified multiple variants and prioritized seven - two in the 474 promoter, four in the 5'UTR, and one in the 3'UTR – for functional studies (Table 2 and 475 Figure S7). All SNVs in regulatory regions were observed in the heterozygous state. The 476 selection criteria we applied for prioritization were analogous to those used for 477 nonsynonymous variants. In vitro evaluation in HEK-293 AD cells using reporter assays, in 478 which we cloned either the promoter-5'UTR upstream or the 3'UTR downstream of the 479 luciferase coding sequence, identified two 5'UTR variants, c.-361G>A and c.-133T>C, that 480 significantly reduced luciferase activity when compared to the WT sequence (Figure 5A). In 481 contrast, the 3'UTR variant c.*1455C>T, which was predicted to create new miRNA binding 482 sites, did not produce any effect on luciferase activity when expressed alongside the 483 identified miRNAs (Figure S8), indicating that it does not impair PAM mRNA stability and 484 expression. The c.-361G>A variant was identified in two patients with gigantism and in one 485 individual with a non-functioning PA, while the c.-133T>C variant was present in a pediatric 486 subject who also harbored the p.Phe31Tyr variant and was affected by CD (NIH36, Table 1); 487 this genotype will be identified as c.-133T>C(;)p.Phe31Tyr. Based on in vitro enzyme 488 assays, the p.Phe31Tyr missense SNV diminished neither PHM nor PAL activity to a 489 significant extent (Figure 3A and Table 3).

490



491

492 Figure 5. WT and mutant *PAM* promoter activity

493 A 5 kb PAM promoter-5'UTR WT sequence was cloned upstream of a luciferase reporter. Six mutant 494 constructs were created by site-directed mutagenesis. The constructs were transiently transfected 495 into HEK-293 AD cells together with a Renilla luciferase reporter for normalization. Firefly and Renilla 496 luciferase activities were measured 24 h post-transfection. Two SNVs, c.-361G>A and c.-133T>C, 497 have significantly lower transcriptional activity than the WT hybrid transcript. Mock, empty pRMT-Luc 498 vector. Differences between experimental groups were analyzed by 1-way ANOVA with Dunnett's 499 post hoc test, using WT as the control group. RLU, relative luciferase activity. *, p = 0.0443; **, p = 500 0.0019; ***, p = 0.0005.

501

502 Quantification of PHM and PAL catalytic activities in serum

503 Endoproteolytic cleavage of PAM-1 can occur within the regulated secretory pathway and 504 after the endocytic retrieval of PAM-1 from the cell surface [16-18]. In addition, several *PAM* 505 splice variants encode soluble bifunctional PAM proteins that are secreted along with the 506 peptide hormones stored in secretory granules [10]. As a result, both PHM and PAL activity 507 are readily detected in human serum [19, 20]. The anti-coagulants added during the 508 collection of plasma make the accurate assessment of PHM activity in plasma very difficult.

As a result, we could only assess PHM and PAL activity in the small number of serum samples collected from our cohort. As shown in Figure 6, we measured PHM and PAL activity and calculated the ratio of PAL to PHM activity for 13 subjects (11 affected individuals/carriers and two WT controls). To control for the fact that the serum samples assayed had been stored for varying periods of time, we evaluated the statistical significance of changes in activity by normalizing PAL activity to PHM activity.

515



516

517 Figure 6. PHM and PAL activity in human sera

Assays for PHM and PAL activity were carried out on sera from individuals harboring variants showing deleterious effects in *in vitro* assays (p.Asp563Gly, p.Arg703Gln, and p.His778fs), subjects with more benign variants (p.Val27IIe and p.Val49Leu) and controls (WT). In NIH36, the p.Phe31Tyr variant occurs along with the 5'UTR c.-133T>C variant. The dashed line at 0.5 indicates the activity level expected with one completely inactive allele. WT, wild-type.

523

524 Several serum samples were available from patients with two SNVs that resulted in the 525 almost total loss of the PAL activity of PAM-1, p.Arg703Gln (three samples) and p.His778fs 526 (two samples); consistent with our *in vitro* activity assays of transiently expressed PAM-1 527 and the total elimination of one allele, serum PAL activity fell by a factor of two for both

528 variants. Also consistent with the data shown in Table 3, serum PHM activity was unaffected 529 in the p.Arg703GIn variant and was reduced substantially in the p.His778fs variant. Three of 530 the serum samples available came from subjects carrying SNVs located in PHMcc, but none 531 significantly reduced the PHM or PAL activity of transiently expressed PAM-1. Strikingly, 532 both PHM and PAL activities were reduced in the serum sample from NIH36, who harbors 533 an expression-inhibiting 5'UTR SNV (c.133T>C) in addition to the p.Phe31Tyr SNV. Taken 534 together, our data indicate that the observed reduction in serum PHM and PAL activity can 535 be attributed to the 5'UTR SNV, thus confirming the *in vitro* finding. Sera from three different 536 subjects harboring the p.Asp563Gly variant showed substantial, but variable, reductions in 537 both PHM and PAL activity. A better interpretation of serum PHM and PAL activity requires 538 further insight into its multiple potential sources. Altogether, analysis of the limited set of 539 serum samples available emphasizes the utility of using a wide variety of in vitro systems to 540 evaluate the functional effects of PAM SNVs.

541

542 Loss of heterozygosity (LOH) studies

543 Next, we explored whether PAM acts as a tumor suppressor gene and requires a second 544 somatic hit affecting the WT allele, as would be expected by the Knudson two-hit hypothesis 545 [21]. Therefore, we extracted genomic DNA from the PAs surgically removed from 546 individuals harboring variants with demonstrated deleterious effects and studied LOH by 547 Sanger sequencing. The available tumors that we analyzed harbored the following variants: 548 c.-133T>C(;)p.Phe31Tyr, p.Ser539Trp, p.[Gly552Arg];[Asp563Gly], and p.Asp563Gly (n = 1 549 tested for each SNV). We did not identify loss of the WT allele, suggesting that PAM does 550 not behave like a typical tumor suppressor but may rather be a haploinsufficient gene. 551 Unexpectedly, in the individual compound heterozygous for p.[Gly552Arg];[Asp563Gly], we 552 observed loss of the mutant allele causing the change at codon 552 (Figure S9). This likely 553 represents an instance of in vivo reversion to normal of an inherited variant (revertant 554 mosaicism) [22].

555

556 *PAM* SNVs are significantly associated with a hyperfunctioning pituitary gland

557 Having detected multiple SNVs with deleterious effects on PAM protein function in our 558 cohort, we decided to test whether SNVs within the PAM locus are statistically associated 559 with a pituitary disease phenotype in a larger and more heterogeneous cohort. To this end, 560 we interrogated the UKBB, a powerful resource for genetic association analyses that 561 contains exome sequencing data of 200,643 adult individuals with different and well-562 annotated pathologies. First, we performed a gene-based association study using the 563 sequence kernel association test (SKAT) [23, 24]. For this analysis, we considered ICD-10 564 codes associated with sellar lesions (D352, E220, E221, E222, E229, E237, E240, covering 565 the following conditions: benign neoplasm of pituitary gland; acromegaly and pituitary 566 gigantism; hyperprolactinemia; syndrome of inappropriate secretion of antidiuretic hormone; 567 hyperfunction of pituitary gland, unspecified; disorder of pituitary gland, unspecified; and 568 pituitary-dependent Cushing's disease, respectively) and SNVs at the PAM locus for which 569 we assigned a weight based on their detrimental effect on protein (see Methods for details). 570 We set a MAF cutoff of 0.1% for rare variants. PAM was identified as significantly associated 571 (exome-wide) with a diagnosis of hyperfunction of the pituitary gland (E229, $p = 1.71 \times 10^{-77}$, 572 Figure 7A). Next, we performed single-variant analyses restricted to rare (MAF < 1%) PAM 573 variants with a predicted deleterious effect (CADD_PHRED score ≥15). We identified nine 574 missense heterozygous variants (Figure 7B and Figure S10, Table S6), four in PHMcc 575 (p.Ser97Arg, p.Arg190His, p.Pro192Arg, p.Val351Met), four in PALcc (p.Gly531Cys, 576 p.lle554Val, p.Val597Met, p.Pro693Leu) and one in the C-terminal non-catalytic region 577 (p.Leu856Pro). The p.Ser97Arg variant is located in the loop connecting the β -strand 578 containing the vicinal His residues that bind Cu_H to the preceding β -strand and the 579 p.Arg190His and p.Pro192Arg variants are both in the short linker that connects the two 580 homologous domains of PHMcc. PHMcc terminates with Val351; although the final three C-581 terminal amino acids are not identified in the crystal structure, removal of four C-terminal 582 residues produces a protein lacking PHM activity. Two of the PAL variants (p.Gly531Cys

and p.IIe554Val) are situated in or near the long loop that forms its hydrophobic substrate binding pocket and connects β -strands 2 and 3 of Blade 1. The other two PAL variants (p.Val597Met and p.Pro693Leu) are contained within the structural repeats that form Blades 2 and 4. A study aimed at understanding the effects of luminal pH on the trafficking of rat PAM identified the juxtamembrane region that encompasses p.Leu856Pro as a key determinant [25].



589

590 Figure 7. Gene- and variant-based association analyses for PAM in the UKBB

(A) Results of SKAT analysis of *PAM* variants for diagnoses of hyperfunction of the pituitary gland
(identified from UKBB fields 41270 and 41204 - primary and secondary ICD-10 diagnoses from
hospitalization records - and 20002 - self-reported diagnosis) in 200,000 UKBB participants. The
SKAT CommonRare algorithm was used for analysis. (B) Significant enrichment for *PAM* pathological
missense *PAM* variants in subjects diagnosed with hyperfunction of the pituitary gland.

596

597 To complement the analyses conducted on the UKBB, we examined the outputs of a gene-598 specific metric, the gene damage index (GDI) [26]. The GDI score predicts the liability of a 599 gene to contain disease-causing mutations by considering the influences of selection and 600 genetic drift [27]. For this analysis, we considered 20 genes that harbor germline or somatic 601 variants known to predispose to PAs in order to estimate a GDI cutoff above which a gene is 602 unlikely to cause a pituitary disease, i.e., it is considered a false positive. *PAM* was reported 603 to have a Phred-scaled GDI score of 3.98, below the calculated cutoff of 4.84 (Table S7).

Therefore, our analysis indicates an intolerance to mutational changes for *PAM* in large population samples, supporting the notion that the observed LOF variants are more likely to contribute to disease.

607

608 <u>Functional analysis of splicing in other rare variants</u>

609 Among the rare SNVs identified in the UKBB, an intronic SNV (c.2746+3A>T) was predicted 610 to disrupt the canonical splice donor site of intron 24 (Figure S11A and Table S6); this SNV 611 was associated with a diagnosis of acromegaly and pituitary gigantism (E220). Our splicing 612 analysis ascertained that this SNV caused skipping of exon 24 in most transcript molecules; 613 the expected outcome is the in-frame deletion of 19 residues located within the cytoplasmic 614 domain (p.(Ala897_Arg915del)). While the absence of exon 24 does not alter the PHM or 615 PAL activity of PAM, previous studies indicate that tissue-specific splicing at this site occurs 616 in the rat and could affect the trafficking of membrane PAM [28-30]. PAM mRNA expression 617 levels for the mutant allele were about half of WT levels in *in vitro* studies (Figure S11B). 618 Therefore, an individual harboring this variant is predicted to make 25% less biologically 619 active PAM protein than healthy controls; if trafficked correctly, a reduced level of this variant 620 might support normal PAM functions.

621 The finding of two non-coding SNVs affecting *PAM* splicing (albeit with different outcomes) 622 and recent studies underscoring the importance of evaluating splicing defects as a disease 623 mechanism for both conditions of hyper and hypopituitarism [31, 32], prompted us to extend 624 the corresponding functional studies to selected synonymous and intronic variants found in 625 our cohort (Figure S12A and Table S8). The selection criteria were analogous to those 626 applied for other prioritized variants. This analysis did not reveal any splicing impairment. 627 We observed only a possible reduction in mRNA expression by the c.195G>T allele (Figure 628 S12B), but this was not subsequently confirmed by qPCR studies (Figure S12C).

Taken together, these findings indicate that impairment of PAM function or expression viaabnormal splicing is not frequently associated with PAs.

631

632 Discussion

Studies over the last 30 years have identified a small number of germline and somatic genetic defects associated with the development of different types of PAs. However, the majority of tumors still do not have a known genetic cause [8]. Here, we report that several rare variants in the *PAM* gene are associated with pituitary gland hypersecretion and that most have a deleterious effect on protein function.

638

639 We initially identified a deleterious missense PAM variant (p.Arg703Gln) in a FIPA family 640 with a severe form of childhood-onset pituitary gigantism in which other established causes, 641 such as X-linked acrogigantism (X-LAG) due to duplications involving GPR101, germline AIP 642 mutations/deletions or others, had been ruled out [33, 34]. Among the genes filtered from the 643 WES screening, the high level of PAM expression in the pituitary gland and its known 644 functions in the pituitary and other endocrine cells made PAM the prioritized candidate. A 645 bifunctional enzyme that is essential for the biosynthesis of multiple pituitary and 646 hypothalamic peptide hormones, PAM affects regulated secretion and is involved in the 647 biogenesis of secretory granules [10, 11, 35, 36]. Based on site-directed mutagenesis and 648 crystallographic studies of rat PALcc, this Arg residue (Arg 706 in rat PAM) is located at the 649 active site and participates in substrate binding; site-directed mutagenesis of this residue to 650 GIn reduced the activity of PALcc by a factor of four, and mutagenesis to Ala decreased 651 activity by 97% versus WT [13]. Or functional studies on bifunctional human PAM with the 652 Arg703 to Gln mutation revealed an even greater decrease in its PAL activity (1% relative to 653 WT human PAM), while retaining fully normal PHM activity.

654

This intriguing finding prompted us to explore whether LOF *PAM* variants (SNVs and CNVs) were associated with other types of anterior pituitary adenomas, occurring both in familial and sporadic settings. No other likely deleterious *PAM* SNVs were observed in the familial cases examined, making the estimated frequency of *PAM* LOF variants in our FIPA kindreds

5.56% (1/18). A very rare VUS, p.Pro412Leu, located within the linker region connecting the
two enzymatic domains was identified in a heterogeneous FIPA kindred.

661

We detected six germline SNVs with deleterious effects on protein function/expression in sporadic PA cases. Two variants (p.Ser539Trp, p.Asp563Gly) are relatively common in the general population (global MAF range: 0.42-3.11%). The remaining four variants are very rare (MAF < 0.01%), were found in one subject each, and were significantly enriched in our cohort compared to the general population. Two of these variants (p.Gly552Arg and p.Phe759Ser) were identified in subjects with GH excess (2/173, frequency: 1.16%) and two (c.-133T>C and p.His778fs) in cases with pediatric CD (2/81, frequency: 2.47%).

669

670 The p.Ser539Trp and p.Asp563Gly mutants were previously implicated as major risk factors 671 for type 2 diabetes [37, 38], and an important question is whether these proteins are 672 enzymatically active. When introduced into human PAM-1 and assayed in cell lysates, the 673 p.Ser539Trp variant had 50% of normal PHM activity, lacked detectable PAL activity, and 674 was not normally sialylated, suggesting its abnormal intracellular trafficking. When 675 expressed as a soluble protein containing both PHMcc and PALcc, secretion of the 676 p.Ser539Trp protein was not detected, precluding assessment of its catalytic activity [15]. 677 We prepared two independent p.Ser539Trp plasmid constructs, sequenced both and verified 678 that both constructs were correct. The p.Ser539Trp mutation disrupted the normal trafficking 679 of membrane PAM; when present in the soluble protein, the same variant may inhibit its 680 secretion [15]. Using an assay to quantify PAM activity (PHM followed by PAL) by measuring 681 glyoxylate production from hippuric acid, Thomsen et al. reported that the p.Asp563Gly 682 mutation was about 50% active [15]. Our assays, which assess PHM and PAL activity 683 separately, showed that the PHM activity of p.Asp563Gly was slightly less than half that of 684 WT PAM, while its PAL activity was only one seventh that of WT PAM.

685

686 Our in vitro functional tests indicated an impairment in enzymatic activity for five missense 687 SNVs and the splicing variant (in PAL). PAM expression was decreased for two 5'UTR 688 variants and the COOH-terminal region splicing variant. In addition, glycosylation was 689 abnormal for four of the five missense SNVs. Experimental truncations used to define the C-690 terminus of rat PALcc are consistent with the lack of PAL activity observed for p.His778fs, 691 with the same inability of the truncated rat protein to fold correctly, thereby preventing its 692 secretion [39]. Our functional data indicate a similar behavior for the human variant, along 693 with a significant reduction in PHM activity.

694

695 We also showed that measurement of PHM and PAL activity in the serum of subjects 696 harboring PAM variants correlates well with the corresponding values for each single variant 697 determined using the PEAKrapid assay system. The CD case that harbored a regulatory 698 variant reducing PAM expression was instructive in this regard. In that case, both PHM and 699 PAL activities were lowered to the same extent (about 40% compared to WT), with the PAL 700 to PHM ratio showing a normal value, suggesting that enzymatic activity was not affected. 701 These observations indicate that it is valuable to explore whether assays of PHM and PAL 702 activity in sera could be used as a biomarker of pituitary disease. The recent development of 703 an efficient high-throughput amidation assay [20] could aid in this endeavor.

704

705 The association of loss-of-function PAM SNVs with PAs was further explored by screening 706 200,000 exomes from the UKBB. Supporting our findings, PAM was significantly associated 707 with a diagnosis of pituitary hyperfunction (ICD-10 code E229) and nine rare (MAF < 1%) 708 missense variants, all predicted to be pathogenic, were associated with diagnoses of sellar 709 lesions. Although the UKBB cohort has an inherent selection bias towards healthy 710 volunteers, and disease annotation may be self-reported in some cases or only after hospital 711 admission in others (thereby potentially excluding mild or undiagnosed pituitary 712 hypersecretion diagnoses), the validation of our findings related to PAM variants in an 713 independent cohort more representative of the general population strengthens the observed

associations. Based on previous studies, each of the nine *PAM* variants identified in the UKBB (four in PHMcc, four in PALcc, and one in the juxtamembrane region of the luminal domain) is expected to disrupt enzymatic activity or trafficking of membrane PAM bearing these mutations.

718

719 We did not observe LOH for PAM variants. This suggests that PAM does not behave as a 720 classical tumor suppressor gene, leading us to propose that pathogenic LOF PAM variants 721 act as haploinsufficient alleles. This hypothesis is supported by in silico predictions (HI and 722 HIPred scores for PAM are 0.588 and 0.7057, respectively) [40, 41], and by previous 723 observations that Pam haploinsufficiency impairs several interdependent organ systems in 724 $PAM^{+/-}$ mice. Although a complete lack of *Pam* is not compatible with life [42], mice with a 725 single functional copy of Pam developed increased adiposity and mild glucose intolerance 726 with age [42], were deficient in their ability to maintain body temperature in the cold [43], and 727 showed an increase in anxiety-like behavior [44]; these findings are consistent with defects 728 in β -cell function, the vascular system, and neuronal/neuroendocrine function, respectively. 729 Production of the few amidated peptides tested was not greatly altered by PAM 730 heterozygosity [42, 45, 46], but the production of amidated TRH in the hypothalamus was 731 compromised and the mice were deficient in their pituitary response to hypothyroidism [43]. 732 Moreover, pituitary levels of POMC-derived amidated peptides (diAc-a-MSH, a-MSH, and 733 JP) were significantly increased in PAM^{+/-} mice [46]. These data, together with our 734 observation that rare and functionally deleterious *PAM* SNVs are associated with anterior 735 pituitary hyperfunction, suggest that the pituitary gland is particularly sensitive to PAM 736 haploinsufficiency. Moreover, they indicate that changes in gene expression associated with 737 PAM heterozygosity are tissue-specific and that both amidation-dependent and amidation-738 independent mechanisms (for instance, the secretagogue-mediated translocation of the 739 soluble cytoplasmic PAM fragment to the nucleus affecting gene expression in a cell-type 740 specific manner) [11, 47, 48] likely underlie the described deficits. It will be interesting to

study in further detail whether any of the phenotypes observed in PAM^{+/-} mice are also
present in individuals with PAs that harbor LOF *PAM* variants.

743

744 Limitations to our current study include the fact that only a few subjects with sporadic non-745 functioning tumors and families with multiple endocrine neoplasia were screened. To better 746 estimate the prevalence of PAM variants and their possible contribution to pituitary 747 tumorigenesis, the search for *PAM* variants needs to be extended to those subtypes as well 748 as cohorts with hyperprolactinemia (tumoral or non-tumoral), the most common form of 749 pituitary hypersecretion. In particular, it would be interesting to better assess the risk that the 750 relatively common p.Asp563Gly variant confers to the development of pituitary 751 hyperfunction, particularly in the homozygous state. The variable PAL activity measured in 752 PA subjects that were heterozygous for this variant suggests that other factors, such as 753 genetic, biochemical or dietary (e.g., copper or vitamin C availability, hypoxia) [19], 754 contribute to the regulation of PAM expression and/or activity and, hence, predisposition to 755 pituitary dysfunction and potentially tumorigenesis. Second, our LOH and serum activity 756 analyses were limited to the small number of available PAs and serum samples, 757 respectively. It will be important to screen more tumors harboring deleterious PAM variants 758 to definitively exclude the absence of LOH. Likewise, assessing circulating PHM and PAL 759 activity in more PAM variant carriers will better define their risk profile. Third, the question of 760 how disordered PAM function leads to increased hormonal secretion and/or pituitary tumor 761 development remains to be determined. PAM is a complex, multifunctional protein involved 762 in several pathways related to the regulation of secretion; disruption of one or more of these 763 pathways could play a role in hormonal hypersecretion (Figure 8).

764



765

Figure 8. Biological processes and cellular components that might be affected by PAM haploinsufficiency in pituitary hormone-secreting cells

768 The trafficking of integral membrane PAM and pituitary hormones through the regulated secretory 769 pathway is depicted. Immature secretory granules (iSG) budding from the trans-Golgi network (TGN) 770 contain prohormones and processing enzymes like the prohormone convertases (PCs), granins 771 [chromogranins A and B (ChgA/B) and secretogranins II and II], and PAM. Mature secretory granules 772 (mSG) release their soluble content during regulated exocytosis (the yellow lightning bolt represents 773 the external stimulus triggering secretion). Basal rates of hormone secretion from pituitary cells are 774 less than 1% of the cell content/hour. Although PAM appears on the cell surface during exocytosis, its 775 rapid endocytosis means that very little PAM remains on the plasma membrane at steady-state. 776 Cleavage by secretase-like enzymes can generate a soluble, cytosolic fragment of PAM that can 777 enter the nucleus, where it relays information about the status of the secretory granule pool. Several

in vitro studies have shown that PAM misexpression can affect a variety of steps in the regulated secretory pathway; these are highlighted in red in the cartoon and include SG formation, basal and stimulated secretion, actin cytoskeleton organization, and gene expression. ER, endoplasmic reticulum; GH, growth hormone; MVB, multivesicular body.

782

783 In our study pathological PAM variants were associated with hypersecretion of both 784 amidated and non-amidated pituitary hormones, which suggests that the altered PAM 785 function may affect a different target than the hormones themselves. Granin proteins, 786 including chromogranin A and B are crucial factors in hormonal secretion. Chromogranin A-787 derived peptides such as pancreastatin are themselves targets for amidation by PAM [49], 788 such that changes in PHM and PAL function could alter the packaging and release of 789 hormones contained in secretory granules. Separately, the linker region connecting the PHM 790 and PAL enzymes is O-glycosylated and pH sensitive and is known to influence PAM 791 function and its effects on vesicular trafficking [50].

792 In AtT-20 cells, expression of the PAM-1 isoform without soluble PHM and PAL leads to 793 accumulation of uncleaved POMC in the trans-Golgi network; however, while PAM-1 794 expression decreased secretagogue-stimulated secretion by mature granules, it increased 795 basal secretion of larger POMC peptides [35]. More recently, it has been shown that in atrial 796 myocytes proANP storage is a highly PAM-dependent process even though neither proANP 797 nor ANP itself are amidated proteins. Also, in murine atrial cells devoid of PAM that have 798 depleted proANP storage, the reintroduction of PAM facilitated proANP storage. Crucially, 799 this effect occurred irrespective of whether normal or enzymatically inactivated PAM was 800 used [51, 52]. Interestingly, the depletion of proANP in the absence of PAM was 801 unaccompanied by decreased proANP mRNA or protein biosynthesis, but rather occurred 802 due to 3-fold increased basal ANP secretion. Bäck, Mains & Eipper recently suggested that 803 PAM may also have a role as a cargo receptor that directly binds to and protects proANP 804 soon after its synthesis in the rough endoplasmic reticulum through to newly formed 805 granules [9, 51]. A potential role for PAM as a cargo receptor in pituitary cells remains to be

806	explored. Taken together, these data underline the multiple roles that PAM can play in
807	secretion of hormones. Studies of emerging PAM actions will be needed to address the
808	influence of genetic variants in this study on PAM-mediated pituitary hormone release.
809	
810	In conclusion, PAM was identified as a candidate gene associated with pituitary
811	hypersecretion. Our comprehensive analysis of the impact of multiple PAM variants on
812	protein function can also improve our understanding of other endocrine disorders recently
813	linked to PAM defects, such as type 2 diabetes. Together, these new results raise the
814	prospect of therapeutically targeting PAM function to influence disease in the pituitary and

815 elsewhere across the endocrine system.

817 Materials and Methods

818

819 The study population consisted of index cases and a validation cohort.

The index cases were part of a three member FIPA acro-gigantism family referred to the National Institutes of Health Clinical Center (NIHCC) as part of the Undiagnosed Diseases Program (UDP) [53-55]. The presence of germline SNVs/CNVs in genes known to predispose to pituitary tumors (*AIP*, *GPR101*, *CDKN1B*, *MEN1*, *PRKAR1A*, *GNAS*, and *DICER1*) had been previously ruled out in all affected individuals.

825

826 The validation cohort consisted of 359 individuals with PAs (Table S1). Germline DNA was 827 studied in 299 unrelated individuals with sporadic PAs, in 17 FIPA families (including 19 828 individuals), and in three families with syndromic presentations of PAs and other endocrine 829 tumors (MEN-like syndromes) [7, 56]. Among the sporadic cases, 173 had somatotroph 830 adenomas (40 had pituitary gigantism), 84 had Cushing disease associated with corticotroph 831 adenomas (CD, 81 were pediatric - age < 18 years at diagnosis - and one had Nelson 832 syndrome), four had silent corticotroph adenomas, 25 had lactotroph adenomas (six were 833 pediatric, one was a carcinoma), and 13 had clinically non-functioning or silent adenomas 834 (one was pediatric). Somatic PA DNA was available from additional 38 subjects with 835 sporadic acromegaly; five of them had matched germline DNA [7, 57]. Twenty-two of the 836 pediatric CD cases (one familial and 21 sporadic) had matched tumor DNA available [56]. 837 Subjects for the study were recruited from the Centre Hospitalier Universitaire (CHU), 838 University of Liège (231), the NIH (90), and the Bicêtre Hospital and Foch Hospital Paris 839 (38).

840

UDP patients provided written informed consent under clinical protocol 76-HG-0238, "Diagnosis and Treatment of Patients with Inborn Errors of Metabolism and Other Genetic Disorders", approved by the NHGRI Institutional Review Board. Other individuals from the NIH were recruited between 1997-2017 under research protocol 97-CH-0076

(ClinicalTrials.gov: NCT00001595). The study was approved by the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) Institutional Review Board and by the Ethics Committee of the University of Liège, Belgium. Affected subjects or their relatives signed informed consent or assent forms approved by the local ethics committee. Parents and siblings of the affected individuals were also recruited, when appropriate and available.

851

852 DNA sequencing

853 Index cases: DNA was extracted from peripheral whole blood samples of the twin probands 854 affected with gigantism from generation II, their father, two unaffected siblings, and the three 855 individuals from generation III (sons of II-2). Whole exome sequencing (WES) was 856 performed by a commercial vendor (Axeq Technologies, Rockville, Maryland) using the 857 TruSeg Human Exome 62 Mb capture kit for library preparation for individuals from 858 generation I and II. Exome sequencing was completed using the Illumina HiSeg2000 859 platform resulting in raw sequence FASTQ files. WES in individuals from generation III (and 860 in II-2 as control for kit-specific artifacts) was performed using the NimbleGen SeqCap EZ 861 Exome Library v3.0 kit (Roche) for library preparation. Exome sequencing was completed 862 using the Illumina NovaSeq 6000 platform. Alignments were made to human reference 863 assembly GRCh38 using BWA-MEM [58]. Variant calling and joint genotyping were 864 performed using GATK Best Practices (GATK ver. 4.2.3.0, HTSJDK ver. 2.24.1, Picard ver. 865 2.25.4) [59]. The VCF files were annotated with population data from the gnomAD database 866 (ver. 3.1.2). Functional and predictive annotations were attached using Ensembl Variant 867 Effect Predictor (ver. 102) [60] and the dbNSFP (ver. 4.3a) [61] database. Pathogenicity 868 predictions used in filtering came from SIFT, ClinPred, PolyPhen-2, FATHMM, and 869 Combined Annotation Dependent Depletion (CADD) score. No known disease-causing or 870 damaging biallelic/hemizygous variants segregating to the affected status were identified. 871 Slivar [62] was used to filter the variants and apply pedigree analysis. We prioritized rare 872 heterozygous damaging variants with nonzero pituitary median expression from GTEx that

873 appear in affected individuals for downstream validation and analysis, excluding variants 874 with a population minor allele frequency (MAF) > 1%. Variants reported in the ClinVar and/or 875 the UniProt databases as benign or likely benign were also excluded. PCR (GoTag Green 876 Master Mix, M7123, Promega) and Sanger sequencing (BigDye Terminator 3.1 Cycle 877 Sequencing Kit, 4337456, ThermoFisher Scientific) were used to confirm the PAM variant 878 identified by WES. Sequences were aligned and analyzed using the SeqMan Pro 11.1.0 879 (DNASTAR Lasergene) software. Sequence chromatograms were visualized using 880 SnapGene Viewer ver. 5.0.4.

881

882 Validation cohort: WES data on germline and tumor DNA samples from subjects with CD 883 were generated as described previously [56]. These WES datasets were manually assessed 884 using Integrative Genomics Viewer ver. 2.12.3 platform (Broad Institute) [63]. For all other 885 subjects in the validation cohort, genomic DNA was extracted from peripheral blood and 886 screened for PAM variants by Sanger sequencing. Whenever a PAM pathogenic/likely 887 pathogenic variant was identified and family members were available for analysis, cascade 888 screening was initiated. This led to two instances of genotype-positive family members. In 38 889 individuals with sporadic acromegaly, tumor DNA was available for analysis. However, due 890 to the limited amount of DNA available, Sanger sequencing was targeted to specific regions 891 of *PAM* where the majority of likely pathogenic variants were previously observed (Figure 2), 892 i.e., the proximal promoter and exons 9, 16, 18, 19, 20, and 21. The primers included in 893 Table S2 were used to amplify the promoter and 5'UTR regions, the coding regions and 894 exon-intron junctions by PCR, and for Sanger sequencing. In the available adenomas, DNA 895 was extracted from unstained sections using the Pinpoint Slide DNA Isolation System 896 (D3001, Zymo Research) and loss of heterozygosity (LOH) was investigated by Sanger 897 sequencing. The NC_000005.9(NM_000919.3) reference sequence was used to annotate 898 PAM variants.

899

900 Single cell RNA sequencing (scRNA-seq) analysis: Figure S2A was derived from data 901 published in the NCBI Gene Expression Omnibus (GEO) Series (accession number 902 GSE132224) using methods described in detail [64]. Briefly, scRNA-seg data were derived 903 from freshly dispersed rat anterior pituitary cells from postpubertal males (3,562 cells) and 904 diestrus females (3,334 cells). Cell type clusters were identified using known genetic 905 markers for secretory cell types, folliculostellate cells, erythrocytes, leukocytes, and 906 endothelial cells. Here, we examined the expression levels of the Pam gene and the 907 percentage of cells of each type expressing this gene, plotted as tSNE map [65] and 908 percent-expressing heatmaps using Matlab (R2018b).

909

910 <u>CNV analysis</u>

911 Sixteen pituitary gigantism patients and 121 other individuals with different subtypes of PAs 912 were tested for germline PAM deletions/duplications by droplet digital PCR (ddPCR) using 913 five FAM-labeled TagMan CNV assays spanning the entire PAM gene (Hs03560663 cn in 914 intron 2, Hs03041534_cn in intron 5, Hs06720527_cn in intron 13, Hs06071620_cn in intron 915 16, Hs06028580 cn in exon 25, all ThermoFisher Scientific). The VIC-labeled RPP30 916 (Rnase P) assay (4403326, ThermoFisher Scientific) was used as an internal control. All 917 PCR reactions were prepared using the ddPCR SuperMix for Probes (no dUTP, 1863024, 918 Bio-Rad) and the HindIII restriction enzyme in a QX200 Droplet Digital PCR System (Bio-919 Rad). Results were analyzed with Quanta Soft software ver. 1.7.4.0917 (Bio-Rad).

920

921 Allele phasing

The PacBio long seq run was employed to determine the phasing of *PAM* variants c.718C>T (p.His240Tyr) and c.2276T>C (p.Phe759Ser), located 60 kb apart (exons 9 and 20, respectively), in a person with sporadic gigantism. His parents were not available for genetic studies. Briefly, we employed Single Molecule, Real Time (SMRT) Sequencing technology and a Sequel sequencer (Pacific Biosciences, Menlo Park, CA). The general strategy was to generate a whole-genome library, then perform a hybridization-based pulldown to enrich for

928 the genomic region including the two variants. The probes were targeted against 929 chr5:102,939,611-103,019,811 (hg38 coordinates). This encompasses the positions of the 930 two variants plus an extra 10 kb upstream and downstream for a total of about 83 kb. The 931 biotinylated xGen Lockdown Probes were designed and synthesized by IDT (Coralville, IA) 932 with one probe approximately every 1 kb, for a total of 86 probes. The long reads enable 933 heterozygous variant walking to determine phasing of the variants. The library was 934 constructed according to the Pacific Biosciences protocol given at https://www.pacb.com/wp-935 content/uploads/Procedure-Checklist-%E2%80%93-Multiplex-Genomic-DNA-Target-

936 Capture-Using-IDT-xGen-Lockdown-Probes.pdf, except that SeqCap EZ reagents and the 937 SeqCap Library SR User's Guide (Roche, Indianapolis, IN) were used for the hybridization 938 pulldown. Briefly, the genomic DNA was fragmented using a g-TUBE (Covaris, Woburn, MA) 939 and Pacific Biosciences linear adapters were ligated to the ends to generate a library with an 940 average insert length of about 10 kb. The region of interest was pulled down using a pool of 941 400 attomoles of each of the 86 probes described above. The resulting material was 942 amplified and SMRTbell adapters were ligated to the ends. This library was sequenced on a 943 Sequel (Pacific Biosciences) on a SMRT Cell 1M v2 cell with Sequencing kit 2.1 and a 10 hr 944 acquisition time. The resulting reads were analyzed using the program "Targeted Phasing 945 Consensus" from Pacific Biosciences (https://github.com/PacificBiosciences/targeted-946 phasing-consensus) to perform the read phasing and alignment using CCS reads (circular 947 consensus sequences from 3+ passes), basic subreads, and the hg38 genome for the target 948 region.

949

A male with sporadic acromegaly harbored *PAM* variants c.1654G>A (p.Gly552Arg) and c.1688A>G (p.Asp563Gly), both located in exon 16. To determine the phasing of these closely located SNVs, exon 16 was PCR-amplified from his germline DNA and the PCR product cloned into the TOPO-TA vector. Transformed bacterial colonies were screened for the presence of the variants by PCR and Sanger sequencing.

955

956 Bioinformatic analyses

957 Variant pathogenicity and gene damage predictions: Besides the bioinformatic tools used in 958 the variant prioritization process, Alamut Visual ver. 2.9 software (Interactive Biosoftware) 959 was used for annotation, in silico prediction, and for determining the frequency in public 960 databases of all the PAM variants identified. For nonsynonymous variants, unless specified, 961 the computational verdict was based on the combined outputs of 19 software packages 962 available in Varsome (accessed on 11/24/2022. Five algorithms (Splice Site Finder, MaxEnt, 963 NNSplice, GeneSplicer and Human Site Finder) integrated in Alamut were used for splicing 964 variants. Variants were considered probably damaging or affecting splicing when most of the 965 algorithms agreed; otherwise, they were considered variants of uncertain significance (VUS). 966 The gene damage index (GDI) [26] score for PAM and other genes known to predispose to 967 pituitary tumors was retrieved from The Gene Damage Index Server.

968

969 Spatial clustering analysis: The spatial clustering of a set of variants is obtained by 970 calculating the geometric mean distance between all pairs of variants and normalizing them 971 to the gene's cDNA length (2,922 bp, isoform P19021-5). An empirical p-value is calculated 972 by randomly-generating 100,000 permutations of the variants and comparing their clustering 973 distance against the clustering of the actual variants. As input, we used the 16 prioritized 974 missense and truncating variants found in the index cases and validation cohort and 975 reported in Table 2. We then classified the number of variants located in particular domains 976 of the protein (converted to cDNA coordinates) and counted the number of variants 977 appearing in each domain across all the permutations to calculate an empirical p-value 978 comparing the actual number of variants found in each domain to the number of variants in 979 each domain of the 100,000 permutation analysis.

980

981 <u>Promoter analysis:</u> The computational search for transcription factor binding sites within the 982 promoter region of *PAM* was executed using Genomatix. The MatInspector ver. 3.1 tool of 983 Genomatix (Matrix Library 11.0) was used with a core similarity threshold of 0.75 and an

optimized matrix similarity threshold to search for the presence of transcription factor binding
sites. We limited our search to vertebrate general core promoter elements and the + strand.

987 Protein sequence alignment and structural analysis: Protein sequence alignments were 988 performed using the following sequences from UniProt and Clustal Omega: human PAM-1 989 (P19021-5), chimpanzee PAM-1 (A0A2I3SM67-1), rat PAM-1 (P14925-1), Aplysia PAM-1 990 (Q9NJI4-1), Drosophila PHM (O01404-1) and PAL2 (Q9W1L5-1), and Chlamydomonas 991 PAM (A0A0S2C767-1). The enzymatically active cores for PHM and PAL were aligned. 992 Enzyme activity has been demonstrated for each of these proteins except Aplysia and 993 chimpanzee [39, 66-71]. We included chimpanzee as this species is evolutionarily close to 994 human, rat because both its PHM and PAL domains have been crystalized and extensively 995 analyzed [13, 72], Aplysia and Drosophila to cover other major families, and 996 Chlamydomonas as the most evolutionarily distant species at the boundary of the 997 animal/plant kingdoms. Full-length alignments are available in the Supplemental Methods. 998 Ribbon diagrams of the crystal structures of the catalytic cores of rat PHM (PHMcc) (PDB: 999 10PM) and PAL (PALcc) (PDB: 3FW0) were used to contextualize the identified variants. 1000 3D models were generated using the PyMOL molecular graphics system (Schrödinger, 1001 LLC). Rat PHMcc and PALcc are, respectively, 93% and 92% identical to human PHMcc 1002 and PALcc.

1003

1004 Analysis of PAM SNV enrichment in pituitary diagnoses from the UK Biobank (UKBB) cohort UKBB dataset and disease annotation: The UKBB is a prospective study that recruited 1005 1006 502,611 participants aged 38 to 73 years from 22 sites across the UK with baseline 1007 measures collected between 2006 and 2010 [73]. This research was conducted using the 1008 UKBB Resource (Application Number 48008). The UKBB obtained ethics approval from the 1009 North West Multi-centre Research Ethics Committee (approval number: 11/NW/0382) and 1010 obtained informed consent from all participants. Diagnoses of hyperfunctioning pituitary 1011 diseases were retrieved from hospital inpatient diagnosis fields 41270, 41202, 41204, with

1012 International classification of diseases (ICD-10) codes E220 (acromegaly and pituitary 1013 gigantism), E221 (hyperprolactinemia), E222 (syndrome of inappropriate secretion of 1014 antidiuretic hormone), E229 (unspecified hyperfunction of the pituitary gland), E240-E248-1015 E249 combined as E240 (pituitary-dependent Cushing disease), D352-D359 combined as 1016 D352 (benign neoplasm of pituitary gland), E237 (disorder of pituitary gland), or as self-1017 reported medical condition with codes 1237 (disorder of pituitary gland combined with ICD-1018 10 code E237), 1238 (pituitary adenoma/tumor combined with ICD-10 code D352), 1239 1019 (Cushing's syndrome combined with ICD-10 code E240), 1431 (hyperprolactinemia 1020 combined with ICD-10 code E221), 1429 (acromegaly combined with ICD-10 code E220).

1021

1022 <u>SKAT analysis:</u> Gene-based diagnosis-association analysis was performed on 200,643 1023 individuals for whom exome sequencing data were available using the Sequence Kernel 1024 Association Test (SKAT). The R package SKAT was employed [24]. We used the 1025 CommonRare algorithm for binary traits with the adaptive sum method to account for 1026 common and rare variants within the *PAM* gene, using a MAF cutoff of 0.1% and considering 1027 the weight of the SNVs based on their detrimental effect on protein. SNV weights were 1028 assigned as previously described [74] and adapted as follows:

- weight of 5 for UTR variants, synonymous variants, splice region variants;
- weight of 10 for protein altering variants;
- weight of 20 for start lost, stop lost, in-frame deletions, in-frame insertions;
- for missense variants, weight of 20 + score from combined PolyPhen-2 and SIFT
 predictions: PolyPhen-2 +10 if possibly damaging or +20 if probably damaging or +5
 if unknown; SIFT +20 if deleterious, +0 if tolerated;
- weight of 75 for frameshift variants, nonsense, splice acceptor variants, splice donor
 variants;
- weight of 100 for transcript ablation.

1038 Statistical significance for gene-based tests was set at a Bonferroni-corrected threshold of p

1039 < 2×10^{-6} (threshold for 25,000 genes).

1040

Analysis of SNVs in UKBB: Analysis of SNVs in UKBB individuals with pituitary diagnoses
was performed with PLINK and a custom code in Python ver. 3.7. The CADD v1.660 VEP
plugin was used to provide prediction scores for their detrimental effect. A CADD_PHRED
score of ≥15 and a MAF < 1% were considered as pathogenicity criteria.

1045

1046 Functional characterization of SNVs

1047 <u>Cell lines:</u> The PEAKrapid (ATCC CRL-2828) and HEK-293 AD (ATCC CRL-1573) cells are 1048 lines derived from the Human Embryonic Kidney (HEK)-293 cell line. The PEAKrapid cells 1049 were maintained in Dulbecco's modified Eagle's medium (DMEM)-F12, with 10% fetal 1050 bovine serum (FBS, Hyclone), pen-strep, and HEPES to net 25 mM, while the HEK-293 AD 1051 cells were maintained in DMEM containing low glucose, pyruvate, 2 mM glutamine (Gibco), 1052 with 10% FBS (Gemini Bio Products), and 1% antibiotic–antimycotic (Gibco). Both cell lines 1053 were kept in a humidified atmosphere at 37°C with 5% CO₂.

1054

1055 Vectors and mutagenesis: All cloning reactions were performed using the In-Fusion cloning 1056 system (Clontech). Cloning primers are reported in Table S2. Tissue-specific alternative 1057 splicing generates multiple PAM isoforms [75]. The longest human isoform is a 974 amino 1058 acid integral membrane protein identified as P19021-5 in UniProt. Since a GenBank search 1059 revealed that this isoform is more prevalent than the one chosen as the canonical sequence 1060 (UniProt P19021-1/NM 001177306.2, 973 amino acid-long), we regarded it as human PAM-1061 1, corresponding to what was previously extensively characterized as rat PAM-1, a 976 1062 amino acid integral membrane protein. The ORF expression clone for wild-type (WT) human 1063 PAM-1 (NM_000919.3) cloned into pReceiver-M02 (EX-A3104-M02-GS, Genecopoeia) was 1064 subcloned into the pCMV-FLAG-C vector (635688, Clontech) using the EcoRI and XhoI 1065 restriction sites. The resulting PAM-1 protein has an in-frame C-terminal FLAG tag

1066 (DYKDDDDK) separated from its normal C-terminus by a five amino acid spacer (LEVPA). A 1067 5,373 bp sequence including the human WT PAM promoter (5,000 bp) and 5'UTR (373 bp) 1068 was generated by de novo gene synthesis (Blue Heron Biotech) and cloned into the pRMT-1069 Luc vector (PR100001, Origene) using the EcoRI and MluI restriction sites located upstream 1070 of Firefly luciferase. The WT and mutant (harboring the c.*1455C>T variant) 3'UTRs of 1071 human PAM (2,040 bp) were PCR-amplified from human genomic DNA and cloned into 1072 psiCHECK-2 (Promega) using the XhoI and NotI restriction sites located downstream of 1073 Renilla luciferase. WT and mutant PAM sequences consisting of seven different human 1074 PAM exons (exon 2, 6, 16, 18, 19, 20, 21) together with their flanking intronic sequences 1075 (100/300-bp-long) were PCR-amplified from human genomic DNA and cloned into the 1076 EcoRI-digested pSPL3 vector (Invitrogen). See Supplemental Methods for more details.

1077

1078 Mutagenic primers (reported in Table S2) were used to introduce PAM SNVs using the 1079 QuikChange II XL site-directed mutagenesis kit (Agilent Technologies). Mutagenesis 1080 products were verified by Sanger sequencing. Since our findings (see the Results section) 1081 showed a discrepancy with what was previously reported by Thomsen et al. [15] for the 1082 p.Ser539Trp variant, we prepped the construct harboring this variant twice and sequence-1083 verified it again. To introduce the deletion caused by the splice-altering c.2332-2A>T variant 1084 into the PAM-1_pCMV-FLAG-C vector, the PCR splicing technique was used. A pair of 1085 primers flanking the region where the deletion occurs (entire exon 21) and a pair of 1086 complementary primers comprising a region of -15 bp to +15 bp related to the junction point 1087 are reported in Table S2.

1088

Antibodies: Antibodies used for the various experiments included the following: an affinitypurified rabbit polyclonal antibody (Ab JH629) raised to purified bacterially expressed Exon A (exon 16 in rat *Pam*) [76]; a rabbit polyclonal antibody (Ab JH246) raised to a synthetic peptide corresponding to human PAM(111-126), which is identical to rat PAM(116-131) [77];

1093 a mouse anti-FLAG monoclonal antibody (F1804, Sigma-Aldrich); and an anti-GM130 1094 antibody (#610822, BD Biosciences).

1095

1096 Biochemical analysis of nonsynonymous and splice site-affecting SNVs: Transient 1097 transfection of PAM-1 WT and mutant vectors was performed 24 h after plating using 1098 PEAKrapid cells and TransIT-2020 (MIR 5400, Mirus Bio) [78]. Cells were harvested 24-36 h 1099 after transfection. Protein extraction and western blotting were performed as described 1100 previously [76]. After rinsing with serum-free medium, cells were scraped into serum-free 1101 medium and pelleted. Cell pellets were extracted into ice cold 20 mM Na TES, 10 mM 1102 mannitol, 1% TX-100, pH 7.4 (TMT) containing protease inhibitors and subjected to three 1103 freeze/thaw cycles. Particulate material was removed by centrifugation and protein 1104 concentrations were determined using the bicinchoninic acid assay with bovine serum 1105 albumin (BSA) as the standard. For enzyme assays, lysates were diluted using TMT containing 1 mg/ml BSA. For Western blot analysis, lysates were denatured using 2X or 4X 1106 1107 Laemmli Sample Buffer (Bio-Rad).

1108

PHM and PAL assays were performed using [¹²⁵I]-Ac-Tyr-Val-Gly and [¹²⁵I]-Ac-Tyr-Val-α-1109 1110 hydroxy-Gly with 0.5 µM unlabeled substrate, as described previously [79]. Samples were 1111 assayed in triplicate, within the linear range of the assay. Data for mutants were normalized 1112 to data for human PAM-1 analyzed in parallel. Normalized data from multiple different 1113 transfections were averaged to ensure that each mutant was assessed in at least two 1114 independent transfections. Human serum samples were diluted 10-fold into 20 mM Na TES, 1115 10 mM mannitol, 1 mg/ml bovine serum albumin (PHM diluent). Assays for PHM and PAL 1116 activity were carried out in duplicate or triplicate at pH 5.5; PHM assays included 4 µM 1117 CuSO₄ and PAL assays contained 1 mM CoCl₂.

1118

1119 Analysis of the glycosylation patterns for PAM WT and mutants was performed as described 1120 previously [39]. Cells were harvested 24 h after transfection. Cell pellets were frozen and 1121 thawed in 20 mM Na TES, 10 mM mannitol, pH7.4 containing a protease inhibitor mix. 1122 Following centrifugation at 17,000 g for 20 min at 4°C, the pellets were extracted in TMT with 1123 protease inhibitors and the supernatants were denatured using SDS and digested with 1124 PNGase F or neuraminidase as described by the manufacturer (NEB). For PAM and for 1125 each PAM variant, one aliquot remained on ice (In, Input) and two aliquots were prepared for 1126 enzymatic digestion; both were incubated at 37°C for 60 min, but one received enzyme (N-1127 Gly or Neur) and one did not (Con). After SDS-PAGE and transfer to PVDF membranes, 1128 epitope-tagged PAM and its variants were visualized using a FLAG antibody. Neuraminidase 1129 removes sialic acid from both N-linked and O-linked oligosaccharides. Samples treated with 1130 neuraminidase were analyzed on two separate gels, with the p.Arg703Gln samples 1131 appearing in part on both gels.

1132

1133 Analysis of splicing by minigene assay: Transient transfection of WT and mutant pSPL3 1134 vectors was performed using HEK-293 AD cells and TurboFect (ThermoFisher Scientific). 1135 Cells were transfected 24 h after plating; 24 h after transfection, total RNA was extracted 1136 using the RNeasy Plus Mini Kit (Qiagen). RNA (500 ng) was reverse transcribed to cDNA 1137 using the Superscript III Kit (ThermoFisher Scientific). mRNA synthesis from the plasmids 1138 using the cells' own transcription and splicing machinery led to mRNA products containing 1139 the tested PAM exon flanked by two exons from the pSPL3 vector. Splicing products were 1140 analyzed by RT-PCR using the vector-specific SD6 and SA2 primers (Table S2). The empty 1141 pSPL3 vector was used as negative control.

1142

1143 <u>Analysis of SNVs in regulatory regions by luciferase-based reporters:</u> SNVs located 1144 upstream (promoter and 5'UTR) and downstream (3'UTR) of *PAM* CDS, were investigated 1145 using luciferase-based reporter assays transfected into HEK-293 AD cells. The empty 1146 pRMT-Luc and psiCHECK-2 vectors were used as negative controls. For the 3'UTR

1147 experiments, four microRNA (miRNA) mimics (hsa-miR-138-2-3p, MC12814; hsa-miR-192-1148 3p, MC12893; hsa-miR-3143, MC17293; hsa-miR-556-3p, MC12806; all ThermoFisher 1149 Scientific) were transfected alongside the WT and mutant reporter vectors. Cells were lysed 1150 24 h after transfection and Firefly and/or Renilla luciferase activities were measured using 1151 the Dual-Luciferase Reporter Assay System (Promega) following the manufacturer's 1152 protocol. When appropriate, ratios of Firefly/Renilla luminescence signals, serving as a 1153 measure for reporter activity normalized for transfection efficiency, were determined using a 1154 FLUOstar Omega microplate reader (BMG Labtech).

1155

1156 Immunohistochemistry

Immunofluorescence analysis was performed on histological sections from non-pathological pituitary cells (control). The full protocol has been detailed elsewhere [80]. Briefly, all slides were blocked with 10% normal donkey serum in 1X PBS for 1 h at room temperature and then incubated overnight at 4°C with affinity-purified 1:500 anti-PAM JH629 and anti-GM130.
All slides were incubated for 1 h with 1:500 donkey anti-rabbit 488 and donkey anti-mouse 594 (respectively, A-11055 and A-21207, ThermoFisher Scientific). Slides were imaged at 40× on a Keyence BZ- X710 microscope.

1164

1165 <u>Statistical analysis</u>

1166 All graphs were plotted as mean ± standard error of the mean (SEM). Data distributions 1167 were assessed for approximate normality. Differences between experimental groups were 1168 analyzed by two-tailed Student's t-test or 1-way ANOVA with Dunnett's post hoc test, or 1169 corresponding non-parametric tests, as appropriate. PAM SNV allele frequencies in the 1170 study population were compared with frequencies in the general population reported in the 1171 gnomAD public database using Fisher's exact test or the chi-square test, as appropriate. 1172 Data were analyzed using GraphPad Prism (GraphPad, San Diego, CA, USA). p-values < 1173 0.05 were considered statistically significant.

1174

1175 Acknowledgments

- 1176 The authors would like to thank Steven Coon of the Molecular Genomics Core of 1177 NICHD/NIH for conducting the phasing experiment, the late Mario Amzel (Johns Hopkins 1178 University School of Medicine) for useful comments on the impact of PAM variants on its 3D 1179 structure, Lyssikatos Charalampos and María de la Luz Sierra (NICHD/NIH) for their help 1180 with the collection and preparation of DNA and histopathological samples used in this study; 1181 Emilie Castermans and Leonor Palmeira (CHU de Liège) for genetic and bioinformatic 1182 analyses of FIPA kindreds, and Jean-Francois Bonneville (CHU de Liège, Belgium) for 1183 discussions on the neuroradiological images.
- 1184

1185 Data and Code Availability

- 1186 The code used to conduct the spatial clustering analysis can be found at
- 1187 <u>https://github.com/NICHD-BSPC/spatial_clustering</u>.
- 1188

1189 Web Resources

- 1190 BWA, https://github.com/lh3/bwa
- 1191 CADD, https://cadd.gs.washington.edu/
- 1192 ClinVar, https://www.ncbi.nlm.nih.gov/clinvar/
- 1193 Clustal Omega, https://www.ebi.ac.uk/Tools/msa/clustalo/
- 1194 dbNSFP (ver. 4.3a), http://database.liulab.science/dbNSFP
- 1195 dbSNP, https://www.ncbi.nlm.nih.gov/snp/
- 1196 Ensembl VEP (ver. 102), https://grch37.ensembl.org/info/docs/tools/vep/index.html
- 1197 GATK (ver. 4.2.3.0), https://gatk.broadinstitute.org/hc/en-us/articles/4409678362139-GATK-
- 1198 <u>4-2-3-0-release</u>
- 1199 Genomatix, https://www.genomatix.de/
- 1200 gnomAD (ver. 3.1.2), <u>https://gnomad.broadinstitute.org/</u>
- 1201 Gene Structure Display Server (GSDS 2.0), http://gsds.cbi.pku.edu.cn/
- 1202 GTEx Project, <u>https://www.gtexportal.org/home/</u>

- 1203 HIPred score, <u>https://github.com/HAShihab/HIPred</u>
- 1204 HTSJDK (ver. 2.24.1), https://samtools.github.io/htsjdk/
- 1205 OMIM, https://www.ncbi.nlm.nih.gov/omim
- 1206 PCR splicing technique, http://www.methods.info/Methods/Mutagenesis/PCR_splicing.html
- 1207 Picard (ver. 2.25.4), <u>http://broadinstitute.github.io/picard/</u>
- 1208 PolyPhen-2, http://genetics.bwh.harvard.edu/pph2/
- 1209 Primer3, <u>https://www.ncbi.nlm.nih.gov/omim</u>
- 1210 Protein Molecular Weight, <u>https://www.bioinformatics.org/sms/prot_mw.html</u>
- 1211 Slivar, https://github.com/brentp/slivar
- 1212 The Gene Damage Index (GDI) Server, <u>http://pec630.rockefeller.edu:8080/GDI/</u>
- 1213 The Human Protein Atlas, <u>https://www.proteinatlas.org/</u>
- 1214 UniProt, https://www.uniprot.org/
- 1215 Varsome, <u>https://varsome.com/</u>
- 1216

1217 Declaration of Interests

1218 Dr. Beckers, Dr. Daly, Dr. Faucz, Dr. Stratakis and Dr. Trivellin hold a patent on the GPR101 1219 gene and its function (US Patent No. 10,350,273, Treatment of Hormonal Disorders of 1220 Growth). Dr. Stratakis holds patents on technologies involving PRKAR1A and related genes 1221 causing adrenal, pituitary, and other tumors. In addition, his laboratory has received 1222 research funding support by Pfizer Inc. for investigations on growth-hormone producing 1223 pituitary adenomas. Dr. Stratakis also has consulted within the last 12 months with 1224 Lundbeck Pharmaceuticals and Sync, LLC, and is currently employed by ELPEN 1225 Pharmaceuticals. Dr. Beckers and Dr. Daly have received research funding from Pfizer Inc. 1226 and Novo-Nordisk. Dr. Jaffrain-Rea is part of the advisory board of Recordati Rare diseases 1227 since 2022. The authors declare that they have no conflicts of interest with the contents of 1228 this article.

- 1229
- 1230 Funding

1231 The work was supported by the following funding sources: Society for Endocrinology 1232 equipment grant (to GT); Intramural Research Program, Eunice Kennedy Shriver National 1233 Institute of Child Health and Human Development (NICHD) and National Institute of 1234 Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) Research 1235 projects Z1A HD008920 (to CAS, supporting GT, LCHR, FRF), R01-DK032949 (to BAE and 1236 REM); the Intramural Research Program of the National Human Genome Research Institute 1237 (to CT and WAG); the Daniel Schwartzberg Fund (to REM and BAE); Fonds 1238 d'Investissement pour la Recherche Scientifique (FIRS) of the Centre Hospitalier 1239 Universitaire de Liège (to AFD and AB); Novo Nordisk Belgium Educational Grant, Belgium 1240 (to AFD and AB); the JABBS Foundation, UK (to AB). AFD was supported, in part, by Action 1241 de Recherche Concertée (ARC) Grant 17/21-01 from Liège University.

1242 1243

References

1244 1. Figarella-Branger D, Appay R, Metais A, Tauziede-Espariat A, Colin C, Rousseau A, et 1245 al. [The 2021 WHO classification of tumours of the central nervous system]. Ann Pathol. 2021. 1246 Epub 20211202. doi: 10.1016/j.annpat.2021.11.005. PubMed PMID: 34865882.

Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, et al. Clinical Biology
 of the Pituitary Adenoma. Endocr Rev. 2022. Epub 20220408. doi: 10.1210/endrev/bnac010.
 PubMed PMID: 35395078.

Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High
 prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J
 Clin Endocrinol Metab. 2006;91(12):4769-75. Epub 20060912. doi: 10.1210/jc.2006-1668.
 PubMed PMID: 16968795.

Srirangam Nadhamuni V, Korbonits M. Novel Insights into Pituitary Tumorigenesis:
 Genetic and Epigenetic Mechanisms. Endocr Rev. 2020;41(6). Epub 2020/03/24. doi:
 10.1210/endrev/bnaa006. PubMed PMID: 32201880; PubMed Central PMCID:
 PMCPMC7441741.

Vandeva S, Daly AF, Petrossians P, Zacharieva S, Beckers A. Somatic and germline
 mutations in the pathogenesis of pituitary adenomas. Eur J Endocrinol. 2019;181(6):R235-R54.
 Epub 2019/10/29. doi: 10.1530/EJE-19-0602. PubMed PMID: 31658440.

Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial isolated pituitary adenomas (FIPA)
 and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor
 interacting protein (AIP) gene. Endocr Rev. 2013;34(2):239-77. Epub 20130131. doi:
 10.1210/er.2012-1013. PubMed PMID: 23371967; PubMed Central PMCID: PMCPMC3610678.

Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med.
2014;371(25):2363-74. Epub 20141203. doi: 10.1056/NEJMoa1408028. PubMed PMID: 25470569; PubMed Central PMCID: PMCPMC4291174.

1269 8. Coopmans EC, Korbonits M. Molecular genetic testing in the management of pituitary
 1270 disease. Clin Endocrinol (Oxf). 2022;97(4):424-35. Epub 20220329. doi: 10.1111/cen.14706.
 1271 PubMed PMID: 35349723.

1272 9. Back N, Mains RE, Eipper BA. PAM: diverse roles in neuroendocrine cells,
1273 cardiomyocytes, and green algae. FEBS J. 2022;289(15):4470-96. Epub 20210622. doi:
10.1111/febs.16049. PubMed PMID: 34089560.

1275 10. Kumar D, Mains RE, Eipper BA. 60 YEARS OF POMC: From POMC and alpha-MSH to 1276 PAM, molecular oxygen, copper, and vitamin C. J Mol Endocrinol. 2016;56(4):T63-76. Epub 1277 20151214. doi: 10.1530/JME-15-0266. PubMed PMID: 26667899; PubMed Central PMCID: 1278 PMCPMC4899100.

1279 11. Mains RE, Blaby-Haas C, Rheaume BA, Eipper BA. Changes in Corticotrope Gene
1280 Expression Upon Increased Expression of Peptidylglycine alpha-Amidating Monooxygenase.
1281 Endocrinology. 2018;159(7):2621-39. Epub 2018/05/23. doi: 10.1210/en.2018-00235. PubMed
1282 PMID: 29788427; PubMed Central PMCID: PMCPMC6287594.

12. Faucz FR, Tirosh A, Tatsi C, Berthon A, Hernandez-Ramirez LC, Settas N, et al.
Somatic USP8 Gene Mutations Are a Common Cause of Pediatric Cushing Disease. J Clin
Endocrinol Metab. 2017;102(8):2836-43. Epub 2017/05/16. doi: 10.1210/jc.2017-00161.
PubMed PMID: 28505279; PubMed Central PMCID: PMCPMC5546857.

1287 13. Chufan EE, De M, Eipper BA, Mains RE, Amzel LM. Amidation of bioactive peptides: the
1288 structure of the lyase domain of the amidating enzyme. Structure. 2009;17(7):965-73. Epub
1289 2009/07/17. doi: 10.1016/j.str.2009.05.008. PubMed PMID: 19604476; PubMed Central PMCID:
1290 PMCPMC2993158.

1291 14. Hu B, Jin J, Guo A-Y, Zhang H, Luo J, Gao G. GSDS 2.0: an upgraded gene feature 1292 **Bioinformatics**. Epub visualization server. 2015;31(8):1296-7. 20141210. doi: 1293 10.1093/bioinformatics/btu817. PubMed PMID: 25504850; PubMed Central PMCID: 1294 PMCPMC4393523.

1295 15. Thomsen SK, Raimondo A, Hastoy B, Sengupta S, Dai XQ, Bautista A, et al. Type 2
1296 diabetes risk alleles in PAM impact insulin release from human pancreatic beta-cells. Nat
1297 Genet. 2018;50(8):1122-31. Epub 20180727. doi: 10.1038/s41588-018-0173-1. PubMed PMID:
1298 30054598; PubMed Central PMCID: PMCPMC6237273.

1299 16. Braas KM, Stoffers DA, Eipper BA, May V. Tissue specific expression of rat 1300 peptidylglycine alpha-amidating monooxygenase activity and mRNA. Mol Endocrinol. 1301 1989;3(9):1387-98. Epub 1989/09/01. doi: 10.1210/mend-3-9-1387. PubMed PMID: 2575217.

1302 17. Ferraro F, Eipper BA, Mains RE. Retrieval and reuse of pituitary secretory granule
1303 proteins. J Biol Chem. 2005;280(27):25424-35. Epub 20050519. doi: 10.1074/jbc.M414156200.
1304 PubMed PMID: 15905171.

1305 18. May V, Cullen EI, Braas KM, Eipper BA. Membrane-associated forms of peptidylglycine
1306 alpha-amidating monooxygenase activity in rat pituitary. Tissue specificity. J Biol Chem.
1307 1988;263(16):7550-4. Epub 1988/06/05. PubMed PMID: 3372499.

1308 19. Gaier ED, Kleppinger A, Ralle M, Covault J, Mains RE, Kenny AM, et al. Genetic
1309 determinants of amidating enzyme activity and its relationship with metal cofactors in human
1310 serum. BMC Endocr Disord. 2014;14:58. Epub 20140715. doi: 10.1186/1472-6823-14-58.
1311 PubMed PMID: 25022877; PubMed Central PMCID: PMCPMC4113131.

1312 20. Kaufmann P, Bergmann A, Melander O. Novel insights into peptide amidation and
1313 amidating activity in the human circulation. Scientific Reports. 2021;11(1):15791. Epub
1314 20210804. doi: 10.1038/s41598-021-95305-y. PubMed PMID: 34349173; PubMed Central
1315 PMCID: PMCPMC8338962.

1316 21. Knudson AG. Antioncogenes and human cancer. Proceedings of the National Academy
1317 of Sciences. 1993;90(23):10914-21. Epub 1993/12/01. doi: 10.1073/pnas.90.23.10914. PubMed
1318 PMID: 7902574; PubMed Central PMCID: PMCPMC47892.

1319 22. Hirschhorn R. In vivo reversion to normal of inherited mutations in humans. Journal of
1320 Medical Genetics. 2003;40(10):721-8. Epub 2003/10/22. doi: 10.1136/jmg.40.10.721. PubMed
1321 PMID: 14569115; PubMed Central PMCID: PMCPMC1735296.

1322 23. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for
1323 sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89(1):821324 93. Epub 20110707. doi: 10.1016/j.ajhg.2011.05.029. PubMed PMID: 21737059; PubMed
1325 Central PMCID: PMCPMC3135811.

1326 24. Ionita-Laza I, Lee S, Makarov V, Buxbaum Joseph D, Lin X. Sequence Kernel 1327 Association Tests for the Combined Effect of Rare and Common Variants. The American 1328 Journal of Human Genetics. 2013;92(6):841-53. Epub 20130516. doi: 1329 10.1016/j.ajhg.2013.04.015. PubMed PMID: 23684009: PubMed Central PMCID: 1330 PMCPMC3675243.

1331 25. Bell-Parikh LC, Eipper BA, Mains RE. Response of an integral granule membrane
1332 protein to changes in pH. J Biol Chem. 2001;276(32):29854-63. Epub 20010606. doi:
1333 10.1074/jbc.M103936200. PubMed PMID: 11395514.

1334 Itan Y, Shang L, Boisson B, Patin E, Bolze A, Moncada-Vélez M, et al. The human gene 26. 1335 damage index as a gene-level approach to prioritizing exome variants. Proceedings of the 1336 National Academy Sciences. 2015;112(44):13615-20. Epub 20151019. of doi: 1337 10.1073/pnas.1518646112. PubMed PMID: PubMed Central PMCID: 26483451; 1338 PMCPMC4640721.

1339 27. Alyousfi D, Baralle D, Collins A. Gene-specific metrics to facilitate identification of
1340 disease genes for molecular diagnosis in patient genomes: a systematic review. Brief Funct
1341 Genomics. 2019;18(1):23-9. Epub 2018/10/13. doi: 10.1093/bfgp/ely033. PubMed PMID:
1342 30312370.

1343 28. Eipper BA, Park LP, Dickerson IM, Keutmann HT, Thiele EA, Rodriguez H, et al. 1344 Structure of the precursor to an enzyme mediating COOH-terminal amidation in peptide 1345 biosynthesis. Mol Endocrinol. 1987;1(11):777-90. Epub 1987/11/01. doi: 10.1210/mend-1-11-1346 777. PubMed PMID: 3153462.

1347 29. Stoffers DA, Green CB, Eipper BA. Alternative mRNA splicing generates multiple forms
1348 of peptidyl-glycine alpha-amidating monooxygenase in rat atrium. Proc Natl Acad Sci U S A.
1349 1989;86(2):735-9. Epub 1989/01/01. doi: 10.1073/pnas.86.2.735. PubMed PMID: 2911604;
1350 PubMed Central PMCID: PMCPMC286549.

30. Ciccotosto GD, Hand TA, Mains RE, Eipper BA. Breeding stock-specific variation in
peptidylglycine alpha-amidating monooxygenase messenger ribonucleic acid splicing in rat
pituitary. Endocrinology. 2000;141(2):476-86. doi: 10.1210/endo.141.2.7337. PubMed PMID:
10650926.

1355 31. Brue T, Camper SA. Novel mechanism of pituitary hormone deficiency: genetic variants
1356 shift splicing to produce a dominant negative transcription factor isoform. Eur J Endocrinol.
1357 2021;185(6):C19-C25. Epub 20211126. doi: 10.1530/EJE-21-0949. PubMed PMID: 34597272.

32. Vazquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortes E, Dios E,
Moreno-Moreno P, et al. Splicing Machinery is Dysregulated in Pituitary Neuroendocrine
Tumors and is Associated with Aggressiveness Features. Cancers (Basel). 2019;11(10). Epub
20190926. doi: 10.3390/cancers11101439. PubMed PMID: 31561558; PubMed Central PMCID:
PMCPMC6826715.

33. Franke M, Daly AF, Palmeira L, Tirosh A, Stigliano A, Trifan E, et al. Duplications disrupt
chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism.
Am J Hum Genet. 2022;109(4):553-70. Epub 20220223. doi: 10.1016/j.ajhg.2022.02.002.
PubMed PMID: 35202564; PubMed Central PMCID: PMCPMC9069129.

1367 34. Rostomyan L, Daly AF, Petrossians P, Nachev E, Lila AR, Lecoq AL, et al. Clinical and
1368 genetic characterization of pituitary gigantism: an international collaborative study in 208
1369 patients. Endocr Relat Cancer. 2015;22(5):745-57. Epub 20150717. doi: 10.1530/ERC-15-0320.
1370 PubMed PMID: 26187128; PubMed Central PMCID: PMCPMC6533620.

1371 35. Ciccotosto GD, Schiller MR, Eipper BA, Mains RE. Induction of integral membrane PAM
1372 expression in AtT-20 cells alters the storage and trafficking of POMC and PC1. J Cell Biol.
1373 1999;144(3):459-71. Epub 1999/02/11. doi: 10.1083/jcb.144.3.459. PubMed PMID: 9971741;
1374 PubMed Central PMCID: PMCPMC2132922.

1375 36. El Meskini R, Mains RE, Eipper BA. Cell type-specific metabolism of peptidylglycine
1376 alpha-amidating monooxygenase in anterior pituitary. Endocrinology. 2000;141(8):3020-34.
1377 Epub 2000/08/05. doi: 10.1210/endo.141.8.7620. PubMed PMID: 10919291.

1378 37. Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, et al.
1379 The genetic architecture of type 2 diabetes. Nature. 2016;536(7614):41-7. Epub 20160711. doi:
10.1038/nature18642. PubMed PMID: 27398621; PubMed Central PMCID: PMCPMC5034897.

38. Steinthorsdottir V, Thorleifsson G, Sulem P, Helgason H, Grarup N, Sigurdsson A, et al.
Identification of low-frequency and rare sequence variants associated with elevated or reduced
risk of type 2 diabetes. Nat Genet. 2014;46(3):294-8. Epub 20140126. doi: 10.1038/ng.2882.
PubMed PMID: 24464100.

1385 39. Kolhekar AS, Quon AS, Berard CA, Mains RE, Eipper BA. Post-translational N1386 glycosylation of a truncated form of a peptide processing enzyme. J Biol Chem.
1387 1998;273(36):23012-8. Epub 1998/08/29. doi: 10.1074/jbc.273.36.23012. PubMed PMID:
1388 9722525.

40. Shihab HA, Rogers MF, Campbell C, Gaunt TR. HIPred: an integrative approach to
predicting haploinsufficient genes. Bioinformatics. 2017;33(12):1751-7. Epub 2017/02/01. doi:
10.1093/bioinformatics/btx028. PubMed PMID: 28137713; PubMed Central PMCID:
PMCPMC5581952.

1393 41. Schierup MH, Huang N, Lee I, Marcotte EM, Hurles ME. Characterising and Predicting
1394 Haploinsufficiency in the Human Genome. PLoS Genetics. 2010;6(10):e1001154. Epub
1395 20101014. doi: 10.1371/journal.pgen.1001154. PubMed PMID: 20976243; PubMed Central
1396 PMCID: PMCPMC2954820.

1397 42. Czyzyk TA, Ning Y, Hsu MS, Peng B, Mains RE, Eipper BA, et al. Deletion of peptide
1398 amidation enzymatic activity leads to edema and embryonic lethality in the mouse. Dev Biol.
1399 2005;287(2):301-13. Epub 20051012. doi: 10.1016/j.ydbio.2005.09.001. PubMed PMID:
1400 16225857.

43. Bousquet-Moore D, Ma XM, Nillni EA, Czyzyk TA, Pintar JE, Eipper BA, et al. Reversal
of physiological deficits caused by diminished levels of peptidylglycine alpha-amidating
monooxygenase by dietary copper. Endocrinology. 2009;150(4):1739-47. Epub 20081120. doi:

1404 10.1210/en.2008-1202. PubMed PMID: 19022883; PubMed Central PMCID: 1405 PMCPMC2659272.

44. Gaier ED, Rodriguiz RM, Ma XM, Sivaramakrishnan S, Bousquet-Moore D, Wetsel WC,
et al. Haploinsufficiency in peptidylglycine alpha-amidating monooxygenase leads to altered
synaptic transmission in the amygdala and impaired emotional responses. J Neurosci.
2010;30(41):13656-69. Epub 2010/10/15. doi: 10.1523/JNEUROSCI.2200-10.2010. PubMed
PMID: 20943906; PubMed Central PMCID: PMCPMC2975325.

1411 45. Bousquet-Moore D, Prohaska JR, Nillni EA, Czyzyk T, Wetsel WC, Mains RE, et al. 1412 Interactions of peptide amidation and copper: novel biomarkers and mechanisms of neural 1413 Neurobiol 2010;37(1):130-40. dysfunction. Dis. Epub 20091006. doi: 1414 10.1016/j.nbd.2009.09.016. PubMed PMID: 19815072; PubMed Central PMCID: 1415 PMCPMC2787818.

1416 Yin P, Bousquet-Moore D, Annangudi SP, Southey BR, Mains RE, Eipper BA, et al. 46. 1417 Probing the production of amidated peptides following genetic and dietary copper 1418 manipulations. PLoS One. 2011;6(12):e28679. Epub 20111216. doi: 1419 10.1371/journal.pone.0028679. PubMed 22194882; PMID: PubMed Central PMCID: 1420 PMCPMC3241674.

1421 47. Rajagopal C, Mains RE, Eipper BA. Signaling from the secretory granule to the nucleus. 1422 Crit Rev Biochem Mol Biol. 2012;47(4):391-406. Epub 20120608. doi: 1423 10.3109/10409238.2012.694845. PubMed PMID: 22681236; PubMed Central PMCID: 1424 PMCPMC3920730.

48. Francone VP, Ifrim MF, Rajagopal C, Leddy CJ, Wang Y, Carson JH, et al. Signaling
from the secretory granule to the nucleus: Uhmk1 and PAM. Mol Endocrinol. 2010;24(8):154358. Epub 20100623. doi: 10.1210/me.2009-0381. PubMed PMID: 20573687; PubMed Central
PMCID: PMCPMC2940467.

1429 49. Eipper BA, Stoffers DA, Mains RE. The biosynthesis of neuropeptides: peptide alpha1430 amidation. Annu Rev Neurosci. 1992;15:57-85. Epub 1992/01/01. doi:
1431 10.1146/annurev.ne.15.030192.000421. PubMed PMID: 1575450.

1432 50. Vishwanatha K, Back N, Mains RE, Eipper BA. A histidine-rich linker region in
1433 peptidylglycine alpha-amidating monooxygenase has the properties of a pH sensor. J Biol
1434 Chem. 2014;289(18):12404-20. Epub 20140313. doi: 10.1074/jbc.M113.545947. PubMed
1435 PMID: 24627494; PubMed Central PMCID: PMCPMC4007436.

1436 51. Back N, Luxmi R, Powers KG, Mains RE, Eipper BA. Peptidylglycine alpha-amidating
1437 monooxygenase is required for atrial secretory granule formation. Proc Natl Acad Sci U S A.
1438 2020;117(30):17820-31. Epub 20200713. doi: 10.1073/pnas.2004410117. PubMed PMID:
1439 32661174; PubMed Central PMCID: PMCPMC7395455.

1440 52. Bartels ED, Gotze JP, Mains RE, Eipper BA. Commentary on: Peptidylglycine alpha1441 amidating Monooxygenase is Required for Atrial Secretory Granule Formation. J Clin Cardiol.
1442 2021;2(4):75-80. doi: 10.33696/cardiology.2.022. PubMed PMID: 35098246; PubMed Central
1443 PMCID: PMCPMC8793981.

1444 53. Gahl WA, Markello TC, Toro C, Fajardo KF, Sincan M, Gill F, et al. The National
1445 Institutes of Health Undiagnosed Diseases Program: insights into rare diseases. Genet Med.
1446 2012;14(1):51-9. Epub 20110926. doi: 10.1038/gim.0b013e318232a005. PubMed PMID:
1447 22237431; PubMed Central PMCID: PMCPMC4098846.

54. Gahl WA, Mulvihill JJ, Toro C, Markello TC, Wise AL, Ramoni RB, et al. The NIH
Undiagnosed Diseases Program and Network: Applications to modern medicine. Mol Genet
Metab. 2016;117(4):393-400. Epub 20160122. doi: 10.1016/j.ymgme.2016.01.007. PubMed
PMID: 26846157; PubMed Central PMCID: PMCPMC5560125.

1452 55. Gahl WA, Tifft CJ. The NIH Undiagnosed Diseases Program: lessons learned. JAMA. 2011;305(18):1904-5. doi: 10.1001/jama.2011.613. PubMed PMID: 21558523.

1454 56. Hernandez-Ramirez LC, Gam R, Valdes N, Lodish MB, Pankratz N, Balsalobre A, et al.
1455 Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing's disease.
1456 Endocr Relat Cancer. 2017;24(8):379-92. Epub 20170522. doi: 10.1530/ERC-17-0131. PubMed
1457 PMID: 28533356; PubMed Central PMCID: PMCPMC5510591.

1458 57. Lecoq AL, Bouligand J, Hage M, Cazabat L, Salenave S, Linglart A, et al. Very low
1459 frequency of germline GPR101 genetic variation and no biallelic defects with AIP in a large
1460 cohort of patients with sporadic pituitary adenomas. Eur J Endocrinol. 2016;174(4):523-30.
1461 Epub 20160120. doi: 10.1530/EJE-15-1044. PubMed PMID: 26792934.

1462 58. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. 1463 2013. doi: 10.48550/arxiv.1303.3997.

1464 59. van der Auwera G, O'Connor BD. Genomics in the Cloud: Using Docker, GATK, and 1465 WDL in Terra: O'Reilly Media, Incorporated; 2020.

McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al. The Ensembl
Variant Effect Predictor. Genome Biol. 2016;17(1):122. Epub 20160606. doi: 10.1186/s13059016-0974-4. PubMed PMID: 27268795; PubMed Central PMCID: PMCPMC4893825.

Liu X, Li C, Mou C, Dong Y, Tu Y. dbNSFP v4: a comprehensive database of transcriptspecific functional predictions and annotations for human nonsynonymous and splice-site SNVs.
Genome Med. 2020;12(1):103. Epub 20201202. doi: 10.1186/s13073-020-00803-9. PubMed
PMID: 33261662; PubMed Central PMCID: PMCPMC7709417.

1473 62. Pedersen BS, Brown JM, Dashnow H, Wallace AD, Velinder M, Tristani-Firouzi M, et al.
1474 Effective variant filtering and expected candidate variant yield in studies of rare human disease.
1475 NPJ Genom Med. 2021;6(1):60. Epub 20210715. doi: 10.1038/s41525-021-00227-3. PubMed
1476 PMID: 34267211; PubMed Central PMCID: PMCPMC8282602.

1477 63. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al.
1478 Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-6. Epub 2011/01/12. doi:
10.1038/nbt.1754. PubMed PMID: 21221095; PubMed Central PMCID: PMCPMC3346182.

1480 64. Fletcher PA, Smiljanic K, Maso Previde R, Iben JR, Li T, Rokic MB, et al. Cell Type- and
1481 Sex-Dependent Transcriptome Profiles of Rat Anterior Pituitary Cells. Front Endocrinol
1482 (Lausanne). 2019;10:623. Epub 20190918. doi: 10.3389/fendo.2019.00623. PubMed PMID:
1483 31620083; PubMed Central PMCID: PMCPMC6760010.

1484 65. van der Maaten L, Hinton G. Visualizing High-Dimensional Data Using t-SNE. Journal of 1485 Machine Learning Research. 2008;9:2579-605.

1486 66. Eipper BA, Quon AS, Mains RE, Boswell JS, Blackburn NJ. The catalytic core of
1487 peptidylglycine alpha-hydroxylating monooxygenase: investigation by site-directed mutagenesis,
1488 Cu X-ray absorption spectroscopy, and electron paramagnetic resonance. Biochemistry.
1489 1995;34(9):2857-65. Epub 1995/03/07. doi: 10.1021/bi00009a016. PubMed PMID: 7893699.

1490 67. Fan X, Spijker S, Akalal DB, Nagle GT. Neuropeptide amidation: cloning of a bifunctional
1491 alpha-amidating enzyme from Aplysia. Brain Res Mol Brain Res. 2000;82(1-2):25-34. Epub
1492 2000/10/24. doi: 10.1016/s0169-328x(00)00173-x. PubMed PMID: 11042355.

Han M, Park D, Vanderzalm PJ, Mains RE, Eipper BA, Taghert PH. Drosophila uses two
distinct neuropeptide amidating enzymes, dPAL1 and dPAL2. J Neurochem. 2004;90(1):129-41.
Epub 2004/06/17. doi: 10.1111/j.1471-4159.2004.02464.x. PubMed PMID: 15198673.

Kolhekar AS, Keutmann HT, Mains RE, Quon ASW, Eipper BA. Peptidyl a-hydroxylating
monooxygenase: active site residues, disulfide linkages and a two-domain model of the catalytic
core. Biochemistry. 1997;36:10901-9.

1499 70. Kumar D, Blaby-Haas CE, Merchant SS, Mains RE, King SM, Eipper BA. Early
1500 eukaryotic origins for cilia-associated bioactive peptide-amidating activity. J Cell Sci.
1501 2016;129(5):943-56. Epub 20160119. doi: 10.1242/jcs.177410. PubMed PMID: 26787743;
1502 PubMed Central PMCID: PMCPMC4813317.

1503 71. Luxmi R, Kumar D, Mains RE, King SM, Eipper BA. Cilia-based peptidergic signaling.
1504 PLoS Biol. 2019;17(12):e3000566. Epub 20191206. doi: 10.1371/journal.pbio.3000566.
1505 PubMed PMID: 31809498; PubMed Central PMCID: PMCPMC6919629.

1506 72. Prigge ST, Kolhekar AS, Eipper BA, Mains RE, Amzel LM. Amidation of bioactive
1507 peptides: the structure of peptidylglycine alpha-hydroxylating monooxygenase. Science.
1508 1997;278(5341):1300-5. Epub 1997/11/21. doi: 10.1126/science.278.5341.1300. PubMed
1509 PMID: 9360928.

1510 73. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
1511 resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-9. Epub
1512 20181010. doi: 10.1038/s41586-018-0579-z. PubMed PMID: 30305743; PubMed Central
1513 PMCID: PMCPMC6786975.

1514 74. Curtis D, Bakaya K, Sharma L, Bandyopadhyay S. Weighted burden analysis of exome1515 sequenced late-onset Alzheimer's cases and controls provides further evidence for a role for
1516 PSEN1 and suggests involvement of the PI3K/Akt/GSK-3beta and WNT signalling pathways.
1517 Ann Hum Genet. 2020;84(3):291-302. Epub 20200205. doi: 10.1111/ahg.12375. PubMed PMID:
1518 32020597.

1519 75. Bousquet-Moore D, Mains RE, Eipper BA. Peptidylaycine alpha-amidating 1520 monooxygenase and copper: a gene-nutrient interaction critical to nervous system function. J 1521 Neurosci Res. 2010;88(12):2535-45. Epub 2010/07/22. doi: 10.1002/jnr.22404. PubMed PMID: 1522 20648645; PubMed Central PMCID: PMCPMC3732055.

1523 76. Powers KG, Ma XM, Eipper BA, Mains RE. Identifying roles for peptidergic signaling in 1524 mice. Proc Natl Acad Sci U S A. 2019;116(40):20169-79. Epub 20190827. doi: 1525 10.1073/pnas.1910495116. PubMed PMID: 31455734; PubMed Central PMCID: 1526 PMCPMC6778246.

1527 77. Husten EJ, Eipper BA. The membrane-bound bifunctional peptidylglycine alpha-1528 amidating monooxygenase protein. Exploration of its domain structure through limited 1529 proteolysis. J Biol Chem. 1991;266:17004-10.

1530 78. Katrancha SM, Wu Y, Zhu M, Eipper BA, Koleske AJ, Mains RE. Neurodevelopmental 1531 disease-associated de novo mutations and rare sequence variants affect TRIO GDP/GTP 1532 Human Molecular Genetics. 2017:26(23):4728-40. exchange factor activity. doi: 1533 10.1093/hmg/ddx355. PubMed PMID: 28973398; PubMed Central PMCID: PMCPMC5886096.

1534 79. Kolhekar AS, Mains RE, Eipper BA. Peptidylglycine alpha-amidating monooxygenase:
1535 an ascorbate-requiring enzyme. Methods Enzymol. 1997;279:35-43. doi: 10.1016/s00761536 6879(97)79007-4. PubMed PMID: 9211255.

1537 80. Trivellin G, Bjelobaba I, Daly AF, Larco DO, Palmeira L, Faucz FR, et al.
1538 Characterization of GPR101 transcript structure and expression patterns. J Mol Endocrinol.
1539 2016;57(2):97-111. Epub 20160609. doi: 10.1530/JME-16-0045. PubMed PMID: 27282544;
1540 PubMed Central PMCID: PMCPMC4959428.